<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/stylesheet.css" type="text/css"?>
<?xml-stylesheet href="data:text/css,%3Aroot%7B--art%3Aurl%28%22https%3A%2F%2Fimg.transistorcdn.com%2FgjuJt0SZqcZ65YLzoBQ4RG_w58Nw26nyUoTc_ScTLp8%2Frs%3Afill%3A0%3A0%3A1%2Fw%3A400%2Fh%3A400%2Fq%3A60%2Fmb%3A500000%2FaHR0cHM6Ly9pbWct%2FdXBsb2FkLXByb2R1%2FY3Rpb24udHJhbnNp%2Fc3Rvci5mbS83MDRj%2FMmI3YzBhNWMxYzNl%2FYThjMmFmZWVjNThk%2FM2VjZS5wbmc.webp%22%29%3B--art-scale%3A1%7D" type="text/css"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:podcast="https://podcastindex.org/namespace/1.0">
  <channel>
    <atom:link rel="self" type="application/rss+xml" href="https://feeds.transistor.fm/from-peer-to-ear" title="MP3 Audio"/>
    <atom:link rel="hub" href="https://pubsubhubbub.appspot.com/"/>
    <podcast:podping usesPodping="true"/>
    <title>From Peer to Ear</title>
    <generator>Transistor (https://transistor.fm)</generator>
    <itunes:new-feed-url>https://feeds.transistor.fm/from-peer-to-ear</itunes:new-feed-url>
    <description>From Peer to Ear turns peer-reviewed research into short, plain-language episodes of about ten minutes for practitioners, policymakers, academics, and anyone who wants to stay informed. Each episode takes a study that matters, explains what it found, what it can't tell us, and why it matters.

This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</description>
    <copyright>© 2026 From Peer to Ear</copyright>
    <podcast:guid>eba6fdf2-16c7-5845-8e79-3cfda34ead13</podcast:guid>
    <podcast:locked>yes</podcast:locked>
    <language>en-us</language>
    <pubDate>Fri, 20 Nov 2026 11:58:13 -0800</pubDate>
    <lastBuildDate>Fri, 20 Nov 2026 11:59:03 -0800</lastBuildDate>
    <image>
      <url>https://img.transistorcdn.com/Tm0jOop7OaU7T9oZ0F6w5XY0E57Xow6Hrz0RLO2eiFo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83MDRj/MmI3YzBhNWMxYzNl/YThjMmFmZWVjNThk/M2VjZS5wbmc.jpg</url>
      <title>From Peer to Ear</title>
    </image>
    <itunes:category text="Science">
      <itunes:category text="Social Sciences"/>
    </itunes:category>
    <itunes:category text="Government"/>
    <itunes:type>episodic</itunes:type>
    <itunes:author>From Peer to Ear</itunes:author>
    <itunes:image href="https://img.transistorcdn.com/Tm0jOop7OaU7T9oZ0F6w5XY0E57Xow6Hrz0RLO2eiFo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83MDRj/MmI3YzBhNWMxYzNl/YThjMmFmZWVjNThk/M2VjZS5wbmc.jpg"/>
    <itunes:summary>From Peer to Ear turns peer-reviewed research into short, plain-language episodes of about ten minutes for practitioners, policymakers, academics, and anyone who wants to stay informed. Each episode takes a study that matters, explains what it found, what it can't tell us, and why it matters.

This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</itunes:summary>
    <itunes:subtitle>From Peer to Ear turns peer-reviewed research into short, plain-language episodes of about ten minutes for practitioners, policymakers, academics, and anyone who wants to stay informed.</itunes:subtitle>
    <itunes:keywords>research, peer-reviewed, policy, criminology, evidence-based, science communication</itunes:keywords>
    <itunes:owner>
      <itunes:name>From Peer to Ear</itunes:name>
      <itunes:email>frompeertoear@gmail.com</itunes:email>
    </itunes:owner>
    <itunes:complete>No</itunes:complete>
    <itunes:explicit>No</itunes:explicit>
    <item>
      <title>Why the U.S. Lost Measles Elimination Status</title>
      <itunes:episode>6</itunes:episode>
      <podcast:episode>6</podcast:episode>
      <itunes:title>Why the U.S. Lost Measles Elimination Status</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">bc73e000-63a1-45f8-b2ff-1d56dcb4a4cf</guid>
      <link>https://share.transistor.fm/s/03c4996a</link>
      <description>
        <![CDATA[<p>For 26 years, the United States could say it had eliminated measles. This month, the Pan American Health Organization announced that the status is gone. What does research say about how well the vaccine works, and what could happen next?</p><p>In this episode, Emma and Ezra look at two peer-reviewed studies. A 2025 study in JAMA by Kiang, Lo, and colleagues is a computer simulation: at recent average coverage, measles returned to stay in most simulated runs, while a modest rise in coverage kept it away. A 2021 Cochrane review by Di Pietrantonj and colleagues pooled 138 studies and found the measles vaccine about 95 percent effective after one dose, with no evidence of a link to autism.</p><p>You’ll also hear why “eliminated” doesn’t mean zero cases, why a model is not a forecast, and what neither study can tell us. This episode doesn’t tell you how to vote or what policy to adopt; it covers what the research found.</p><p>This episode is about research, not medical advice. If it touches your own care, talk with your clinician.</p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> a simulation found that at recent average coverage measles could return to stay, and that a modest rise in coverage kept it from returning in the model. A large review found the vaccine effective against measles and found no evidence of a link to autism or encephalitis.</li><li><strong>What they can’t tell us:</strong> what will actually happen. The first study is a model, not a forecast, and it was built on data through 2023. Both leave out what actually raises coverage.</li><li><strong>A question for any proposal:</strong> which coverage numbers is it expected to change, where, and will anyone track whether they did?</li></ul><p><br><strong>For practitioners and policymakers</strong></p><ul><li>The model runs state by state, so it can miss local pockets. A useful question for any community is: what does coverage look like here?</li><li>Neither study tests what gets more families vaccinated. A plan can be judged on whether it names the coverage it expects to change, where, and how results will be tracked.</li><li>The loss of elimination status and the CDC’s case counts are facts reported in the news; the studies here don’t explain why the status was lost.</li><li>This episode is research, not medical advice, and it makes no recommendation about vaccine policy.</li></ul><p><br><strong>The research</strong></p><p><strong>Primary paper (simulation model):</strong> Kiang, M. V., Bubar, K. M., Maldonado, Y., Hotez, P. J., &amp; Lo, N. C. (2025). Modeling reemergence of vaccine-eliminated infectious diseases under declining vaccination in the US. <em>JAMA, 333</em>(24), 2176–2187. <a href="https://doi.org/10.1001/jama.2025.6495">https://doi.org/10.1001/jama.2025.6495</a></p><ul><li>Access: open access; free full text on PubMed Central: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12022863/">PMC12022863</a></li><li>Found: in a simulation of all 50 states and D.C. over 25 years, measles returned to stay in more than eight in ten runs at the recent average coverage the model started from, and did not return when coverage was raised by a modest amount. Limit: it is a model with simplified assumptions, built on coverage data through 2023, and it leaves out spread between states.</li><li>Corresponding author: Nathan C. Lo, Stanford University.</li></ul><p><strong>Companion paper (systematic review):</strong> Di Pietrantonj, C., Rivetti, A., Marchione, P., Debalini, M. G., &amp; Demicheli, V. (2021). Vaccines for measles, mumps, rubella, and varicella in children. <em>Cochrane Database of Systematic Reviews, 2021</em>(11), Article CD004407. <a href="https://doi.org/10.1002/14651858.CD004407.pub5">https://doi.org/10.1002/14651858.CD004407.pub5</a></p><ul><li>Access: free full text on PubMed Central: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8607336/">PMC8607336</a>. We didn’t check access terms on the Cochrane Library site.</li><li>Found: pooling 138 studies, the measles vaccine was about 95 percent effective after one dose and about 96 percent after two, with no evidence of a link to autism or encephalitis and very small risks of fever seizures and a low-platelet condition. Limit: most of the effectiveness evidence is observational, rated moderate certainty, and the searches ended in May 2019.</li><li>Corresponding author: Carlo Di Pietrantonj, ASL AL, Alessandria, Italy.</li></ul><p>The two papers are different kinds of studies, so their numbers shouldn’t be compared side by side. The model assumes the vaccine works; the review is what checks that.</p><p><br><strong>In the news</strong></p><ul><li>ABC News (WPVI/ABC11). <a href="https://abc11.com/story/us-officially-loses-measles-elimination-status-paho-says/20048136/">US officially loses measles elimination status, PAHO says</a> Nov. 17, 2026 (updated Nov. 18).</li><li>Al Jazeera. <a href="https://www.aljazeera.com/news/2026/11/17/us-officially-loses-measles-free-status-after-26-years-amid-outbreak">US officially loses measles-free status after 26 years</a> Nov. 17, 2026.</li><li>Healio. <a href="https://www.healio.com/news/pediatrics/20261117/us-loses-measles-elimination-status-paho-announces">US loses measles elimination status, PAHO announces</a> Nov. 17, 2026.</li><li>HealthDay via MedicineNet. <a href="https://www.medicinenet.com/after_26_years_us_loses_measles_elimination_status/news.htm">After 26 years, U.S. loses its measles elimination status</a> Nov. 17, 2026.</li><li>CDC. <a href="https://www.cdc.gov/measles/data-research/index.html">Measles cases and outbreaks</a>. Counts as of Nov. 19, 2026; they change weekly.</li><li>KFF. <a href="https://www.kff.org/other-health/measles-elimination-status-what-it-is-and-how-the-u-s-could-lose-it/">Measles Elimination Status: What It Is and How the U.S. Could Lose It</a> Nov. 13, 2026.</li><li>CNN via KRDO. <a href="https://krdo.com/health/cnn-health/2026/11/05/wisconsin-infant-is-us-third-measles-related-death-this-week/">Wisconsin infant is US’ third measles-related death this week</a> Nov. 5, 2026.</li><li>Reuters via GVWire. <a href="https://gvwire.com/2026/11/05/wisconsin-reports-infant-death-linked-to-measles-outbreak/">Wisconsin reports infant death linked to measles outbreak</a> Nov. 5, 2026.</li></ul><p><br><strong>The fine print</strong></p><ul><li>The Stanford-led paper is a model built on coverage data through 2023 and published in spring 2025, before this year’s counts. It isn’t a prediction of this outbreak, and its meaning of “comes back to stay” isn’t the Pan American Health Organization’s.</li><li>It leaves out spread between states and extra vaccination during outbreaks, which the authors say likely means it understates outbreaks. It counts infections, including mild ones, and its results lean heavily on how contagious measles is assumed to be and how often it is brought in.</li><li>The Cochrane searches stopped in May 2019, and most of its evidence is observational.</li><li>Neither study tests what raises coverage.</li><li>Case counts change weekly, and sources count measles deaths differently, so the episode leaves the number out. Check the CDC page for current figures.</li></ul><p><br><strong>Credits and links</strong></p><ul><li>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs).</li><li>Outro music: created with Eleven Music.</li><li>Website: frompeertoear.com</li><li>Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we’ll fix it here.</li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>For 26 years, the United States could say it had eliminated measles. This month, the Pan American Health Organization announced that the status is gone. What does research say about how well the vaccine works, and what could happen next?</p><p>In this episode, Emma and Ezra look at two peer-reviewed studies. A 2025 study in JAMA by Kiang, Lo, and colleagues is a computer simulation: at recent average coverage, measles returned to stay in most simulated runs, while a modest rise in coverage kept it away. A 2021 Cochrane review by Di Pietrantonj and colleagues pooled 138 studies and found the measles vaccine about 95 percent effective after one dose, with no evidence of a link to autism.</p><p>You’ll also hear why “eliminated” doesn’t mean zero cases, why a model is not a forecast, and what neither study can tell us. This episode doesn’t tell you how to vote or what policy to adopt; it covers what the research found.</p><p>This episode is about research, not medical advice. If it touches your own care, talk with your clinician.</p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> a simulation found that at recent average coverage measles could return to stay, and that a modest rise in coverage kept it from returning in the model. A large review found the vaccine effective against measles and found no evidence of a link to autism or encephalitis.</li><li><strong>What they can’t tell us:</strong> what will actually happen. The first study is a model, not a forecast, and it was built on data through 2023. Both leave out what actually raises coverage.</li><li><strong>A question for any proposal:</strong> which coverage numbers is it expected to change, where, and will anyone track whether they did?</li></ul><p><br><strong>For practitioners and policymakers</strong></p><ul><li>The model runs state by state, so it can miss local pockets. A useful question for any community is: what does coverage look like here?</li><li>Neither study tests what gets more families vaccinated. A plan can be judged on whether it names the coverage it expects to change, where, and how results will be tracked.</li><li>The loss of elimination status and the CDC’s case counts are facts reported in the news; the studies here don’t explain why the status was lost.</li><li>This episode is research, not medical advice, and it makes no recommendation about vaccine policy.</li></ul><p><br><strong>The research</strong></p><p><strong>Primary paper (simulation model):</strong> Kiang, M. V., Bubar, K. M., Maldonado, Y., Hotez, P. J., &amp; Lo, N. C. (2025). Modeling reemergence of vaccine-eliminated infectious diseases under declining vaccination in the US. <em>JAMA, 333</em>(24), 2176–2187. <a href="https://doi.org/10.1001/jama.2025.6495">https://doi.org/10.1001/jama.2025.6495</a></p><ul><li>Access: open access; free full text on PubMed Central: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12022863/">PMC12022863</a></li><li>Found: in a simulation of all 50 states and D.C. over 25 years, measles returned to stay in more than eight in ten runs at the recent average coverage the model started from, and did not return when coverage was raised by a modest amount. Limit: it is a model with simplified assumptions, built on coverage data through 2023, and it leaves out spread between states.</li><li>Corresponding author: Nathan C. Lo, Stanford University.</li></ul><p><strong>Companion paper (systematic review):</strong> Di Pietrantonj, C., Rivetti, A., Marchione, P., Debalini, M. G., &amp; Demicheli, V. (2021). Vaccines for measles, mumps, rubella, and varicella in children. <em>Cochrane Database of Systematic Reviews, 2021</em>(11), Article CD004407. <a href="https://doi.org/10.1002/14651858.CD004407.pub5">https://doi.org/10.1002/14651858.CD004407.pub5</a></p><ul><li>Access: free full text on PubMed Central: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8607336/">PMC8607336</a>. We didn’t check access terms on the Cochrane Library site.</li><li>Found: pooling 138 studies, the measles vaccine was about 95 percent effective after one dose and about 96 percent after two, with no evidence of a link to autism or encephalitis and very small risks of fever seizures and a low-platelet condition. Limit: most of the effectiveness evidence is observational, rated moderate certainty, and the searches ended in May 2019.</li><li>Corresponding author: Carlo Di Pietrantonj, ASL AL, Alessandria, Italy.</li></ul><p>The two papers are different kinds of studies, so their numbers shouldn’t be compared side by side. The model assumes the vaccine works; the review is what checks that.</p><p><br><strong>In the news</strong></p><ul><li>ABC News (WPVI/ABC11). <a href="https://abc11.com/story/us-officially-loses-measles-elimination-status-paho-says/20048136/">US officially loses measles elimination status, PAHO says</a> Nov. 17, 2026 (updated Nov. 18).</li><li>Al Jazeera. <a href="https://www.aljazeera.com/news/2026/11/17/us-officially-loses-measles-free-status-after-26-years-amid-outbreak">US officially loses measles-free status after 26 years</a> Nov. 17, 2026.</li><li>Healio. <a href="https://www.healio.com/news/pediatrics/20261117/us-loses-measles-elimination-status-paho-announces">US loses measles elimination status, PAHO announces</a> Nov. 17, 2026.</li><li>HealthDay via MedicineNet. <a href="https://www.medicinenet.com/after_26_years_us_loses_measles_elimination_status/news.htm">After 26 years, U.S. loses its measles elimination status</a> Nov. 17, 2026.</li><li>CDC. <a href="https://www.cdc.gov/measles/data-research/index.html">Measles cases and outbreaks</a>. Counts as of Nov. 19, 2026; they change weekly.</li><li>KFF. <a href="https://www.kff.org/other-health/measles-elimination-status-what-it-is-and-how-the-u-s-could-lose-it/">Measles Elimination Status: What It Is and How the U.S. Could Lose It</a> Nov. 13, 2026.</li><li>CNN via KRDO. <a href="https://krdo.com/health/cnn-health/2026/11/05/wisconsin-infant-is-us-third-measles-related-death-this-week/">Wisconsin infant is US’ third measles-related death this week</a> Nov. 5, 2026.</li><li>Reuters via GVWire. <a href="https://gvwire.com/2026/11/05/wisconsin-reports-infant-death-linked-to-measles-outbreak/">Wisconsin reports infant death linked to measles outbreak</a> Nov. 5, 2026.</li></ul><p><br><strong>The fine print</strong></p><ul><li>The Stanford-led paper is a model built on coverage data through 2023 and published in spring 2025, before this year’s counts. It isn’t a prediction of this outbreak, and its meaning of “comes back to stay” isn’t the Pan American Health Organization’s.</li><li>It leaves out spread between states and extra vaccination during outbreaks, which the authors say likely means it understates outbreaks. It counts infections, including mild ones, and its results lean heavily on how contagious measles is assumed to be and how often it is brought in.</li><li>The Cochrane searches stopped in May 2019, and most of its evidence is observational.</li><li>Neither study tests what raises coverage.</li><li>Case counts change weekly, and sources count measles deaths differently, so the episode leaves the number out. Check the CDC page for current figures.</li></ul><p><br><strong>Credits and links</strong></p><ul><li>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs).</li><li>Outro music: created with Eleven Music.</li><li>Website: frompeertoear.com</li><li>Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we’ll fix it here.</li></ul>]]>
      </content:encoded>
      <pubDate>Fri, 20 Nov 2026 11:58:13 -0800</pubDate>
      <author>From Peer to Ear</author>
      <enclosure url="https://media.transistor.fm/03c4996a/53e5d596.mp3" length="13704684" type="audio/mpeg"/>
      <itunes:author>From Peer to Ear</itunes:author>
      <itunes:duration>570</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>For 26 years, the United States could say it had eliminated measles. This month, the Pan American Health Organization announced that the status is gone. What does research say about how well the vaccine works, and what could happen next?</p><p>In this episode, Emma and Ezra look at two peer-reviewed studies. A 2025 study in JAMA by Kiang, Lo, and colleagues is a computer simulation: at recent average coverage, measles returned to stay in most simulated runs, while a modest rise in coverage kept it away. A 2021 Cochrane review by Di Pietrantonj and colleagues pooled 138 studies and found the measles vaccine about 95 percent effective after one dose, with no evidence of a link to autism.</p><p>You’ll also hear why “eliminated” doesn’t mean zero cases, why a model is not a forecast, and what neither study can tell us. This episode doesn’t tell you how to vote or what policy to adopt; it covers what the research found.</p><p>This episode is about research, not medical advice. If it touches your own care, talk with your clinician.</p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> a simulation found that at recent average coverage measles could return to stay, and that a modest rise in coverage kept it from returning in the model. A large review found the vaccine effective against measles and found no evidence of a link to autism or encephalitis.</li><li><strong>What they can’t tell us:</strong> what will actually happen. The first study is a model, not a forecast, and it was built on data through 2023. Both leave out what actually raises coverage.</li><li><strong>A question for any proposal:</strong> which coverage numbers is it expected to change, where, and will anyone track whether they did?</li></ul><p><br><strong>For practitioners and policymakers</strong></p><ul><li>The model runs state by state, so it can miss local pockets. A useful question for any community is: what does coverage look like here?</li><li>Neither study tests what gets more families vaccinated. A plan can be judged on whether it names the coverage it expects to change, where, and how results will be tracked.</li><li>The loss of elimination status and the CDC’s case counts are facts reported in the news; the studies here don’t explain why the status was lost.</li><li>This episode is research, not medical advice, and it makes no recommendation about vaccine policy.</li></ul><p><br><strong>The research</strong></p><p><strong>Primary paper (simulation model):</strong> Kiang, M. V., Bubar, K. M., Maldonado, Y., Hotez, P. J., &amp; Lo, N. C. (2025). Modeling reemergence of vaccine-eliminated infectious diseases under declining vaccination in the US. <em>JAMA, 333</em>(24), 2176–2187. <a href="https://doi.org/10.1001/jama.2025.6495">https://doi.org/10.1001/jama.2025.6495</a></p><ul><li>Access: open access; free full text on PubMed Central: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12022863/">PMC12022863</a></li><li>Found: in a simulation of all 50 states and D.C. over 25 years, measles returned to stay in more than eight in ten runs at the recent average coverage the model started from, and did not return when coverage was raised by a modest amount. Limit: it is a model with simplified assumptions, built on coverage data through 2023, and it leaves out spread between states.</li><li>Corresponding author: Nathan C. Lo, Stanford University.</li></ul><p><strong>Companion paper (systematic review):</strong> Di Pietrantonj, C., Rivetti, A., Marchione, P., Debalini, M. G., &amp; Demicheli, V. (2021). Vaccines for measles, mumps, rubella, and varicella in children. <em>Cochrane Database of Systematic Reviews, 2021</em>(11), Article CD004407. <a href="https://doi.org/10.1002/14651858.CD004407.pub5">https://doi.org/10.1002/14651858.CD004407.pub5</a></p><ul><li>Access: free full text on PubMed Central: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8607336/">PMC8607336</a>. We didn’t check access terms on the Cochrane Library site.</li><li>Found: pooling 138 studies, the measles vaccine was about 95 percent effective after one dose and about 96 percent after two, with no evidence of a link to autism or encephalitis and very small risks of fever seizures and a low-platelet condition. Limit: most of the effectiveness evidence is observational, rated moderate certainty, and the searches ended in May 2019.</li><li>Corresponding author: Carlo Di Pietrantonj, ASL AL, Alessandria, Italy.</li></ul><p>The two papers are different kinds of studies, so their numbers shouldn’t be compared side by side. The model assumes the vaccine works; the review is what checks that.</p><p><br><strong>In the news</strong></p><ul><li>ABC News (WPVI/ABC11). <a href="https://abc11.com/story/us-officially-loses-measles-elimination-status-paho-says/20048136/">US officially loses measles elimination status, PAHO says</a> Nov. 17, 2026 (updated Nov. 18).</li><li>Al Jazeera. <a href="https://www.aljazeera.com/news/2026/11/17/us-officially-loses-measles-free-status-after-26-years-amid-outbreak">US officially loses measles-free status after 26 years</a> Nov. 17, 2026.</li><li>Healio. <a href="https://www.healio.com/news/pediatrics/20261117/us-loses-measles-elimination-status-paho-announces">US loses measles elimination status, PAHO announces</a> Nov. 17, 2026.</li><li>HealthDay via MedicineNet. <a href="https://www.medicinenet.com/after_26_years_us_loses_measles_elimination_status/news.htm">After 26 years, U.S. loses its measles elimination status</a> Nov. 17, 2026.</li><li>CDC. <a href="https://www.cdc.gov/measles/data-research/index.html">Measles cases and outbreaks</a>. Counts as of Nov. 19, 2026; they change weekly.</li><li>KFF. <a href="https://www.kff.org/other-health/measles-elimination-status-what-it-is-and-how-the-u-s-could-lose-it/">Measles Elimination Status: What It Is and How the U.S. Could Lose It</a> Nov. 13, 2026.</li><li>CNN via KRDO. <a href="https://krdo.com/health/cnn-health/2026/11/05/wisconsin-infant-is-us-third-measles-related-death-this-week/">Wisconsin infant is US’ third measles-related death this week</a> Nov. 5, 2026.</li><li>Reuters via GVWire. <a href="https://gvwire.com/2026/11/05/wisconsin-reports-infant-death-linked-to-measles-outbreak/">Wisconsin reports infant death linked to measles outbreak</a> Nov. 5, 2026.</li></ul><p><br><strong>The fine print</strong></p><ul><li>The Stanford-led paper is a model built on coverage data through 2023 and published in spring 2025, before this year’s counts. It isn’t a prediction of this outbreak, and its meaning of “comes back to stay” isn’t the Pan American Health Organization’s.</li><li>It leaves out spread between states and extra vaccination during outbreaks, which the authors say likely means it understates outbreaks. It counts infections, including mild ones, and its results lean heavily on how contagious measles is assumed to be and how often it is brought in.</li><li>The Cochrane searches stopped in May 2019, and most of its evidence is observational.</li><li>Neither study tests what raises coverage.</li><li>Case counts change weekly, and sources count measles deaths differently, so the episode leaves the number out. Check the CDC page for current figures.</li></ul><p><br><strong>Credits and links</strong></p><ul><li>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs).</li><li>Outro music: created with Eleven Music.</li><li>Website: frompeertoear.com</li><li>Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we’ll fix it here.</li></ul>]]>
      </itunes:summary>
      <itunes:keywords>research, peer-reviewed, clinical medicine, measles, vaccines, MMR, elimination status, public health, evidence-based, science communication</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Can One Ebola Vaccine Help Against Another?</title>
      <itunes:episode>5</itunes:episode>
      <podcast:episode>5</podcast:episode>
      <itunes:title>Can One Ebola Vaccine Help Against Another?</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">9b8bc1aa-8865-431c-adc0-855fe1fb45fe</guid>
      <link>https://share.transistor.fm/s/8a0aeca7</link>
      <description>
        <![CDATA[<p>A licensed Ebola vaccine exists. The outbreak now spreading through Congo is caused by a different Ebola virus, and no vaccine is licensed for it. Can the first one help against the second?</p><p><br></p><p>In this episode, Emma and Ezra look at two peer-reviewed studies. A 2026 study in The Lancet by Halbrook, Rimoin, and colleagues followed just over a thousand people in Congo who received the licensed vaccine, and found antibodies that bind to a Bundibugyo virus protein, in different patterns in two cities. A 2025 study in Science Translational Medicine by Mdluli, Rolland, and colleagues tested a different vaccine and found essentially no meaningful binding to that protein. Both measure antibodies in blood, not whether anyone is protected. Along the way: why “sticking” isn’t “blocking,” what an optimist and a realist each take from the data, and the comparison that would settle it.</p><p><br></p><p>This episode is about research, not medical advice.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><br></p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> some vaccinated people in Congo had antibodies that bound to a Bundibugyo protein, in different patterns in two cities, while a second study of a different vaccine found essentially no meaningful binding.</li><li><strong>What they can’t tell us:</strong> whether any vaccine protects anyone against Bundibugyo. Both studies measure antibodies in blood, not illness, and the first has no unvaccinated comparison group.</li><li><strong>A question for any headline:</strong> are they measuring antibodies, or measuring illness?</li></ul><p><br></p><p><strong>For practitioners and policymakers</strong></p><ul><li>Antibody reactivity on a blood test is not a protection test. What answers the question is a comparison group, followed for infection, plus tests of whether antibodies can neutralize the actual virus.</li><li>A neutral question to ask of any proposal: will anyone track the outcomes, and is there a group to compare against?</li><li>A trial that includes the licensed vaccine started in Congo in October; the studies here can’t say what it will find.</li><li>This episode is research, not medical advice, and it makes no recommendation about who should or shouldn’t be vaccinated.</li></ul><p><br></p><p><strong>The research</strong></p><p><em>Primary paper (licensed vaccine, Congo).</em> Halbrook, M., Merritt, S., Hoff, N. A., Mukadi, P., Kompany, J. P., Musene, K., … Rimoin, A. W. (2026). Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus–Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: A longitudinal cohort study. The Lancet, 408(10559), 1019–1028. <a href="https://doi.org/10.1016/S0140-6736(26)01608-9">https://doi.org/10.1016/S0140-6736(26)01608-9</a></p><ul><li><strong>Access:</strong> open access.</li><li><strong>Found:</strong> antibodies that bind to a Bundibugyo protein appeared in about half of vaccinated people in Beni and in about one in three in Mbandaka at one later visit, and the patterns differed. Limit: it measured binding only, with no unvaccinated comparison group, so it can’t say the vaccine caused the pattern or protects.</li></ul><p><br></p><p><em>Companion paper (a different vaccine, trial volunteers).</em> Mdluli, T., Wollen-Roberts, S., Merbah, M., … Rolland, M. (2025). Ebola virus vaccination elicits Ebola virus–specific immune responses without substantial cross-reactivity to other filoviruses. Science Translational Medicine, 17(792), Article eadq2496. <a href="https://doi.org/10.1126/scitranslmed.adq2496">https://doi.org/10.1126/scitranslmed.adq2496</a></p><ul><li><strong>Access:</strong> closed access (subscription or library login). We didn’t find a legal free version; the abstract is indexed in PubMed (PMID 40173257).</li><li><strong>Found:</strong> after two doses of Janssen’s Ebola vaccine, antibodies were mostly specific to the Zaire protein, with essentially no meaningful binding to Bundibugyo. Limit: a different vaccine and lab method, trial volunteers rather than outbreak-affected communities, and funding from the vaccine’s manufacturer.</li></ul><p><br></p><p>The two studies use different vaccines, people, and lab methods, so their numbers shouldn’t be compared side by side.</p><p><br></p><p><strong>In the news</strong></p><ul><li>CDC. <a href="https://www.cdc.gov/ebola/situation-summary/index.html">Ebola Outbreak: Key Facts (situation summary)</a>. Counts as of Nov. 17, 2026 (updated Nov. 19, 2026); they change weekly.</li><li>World Health Organization. <a href="https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON602">Outbreak notice 2026-DON602</a>. May 2026.</li><li>World Health Organization. <a href="https://www.who.int/news/item/17-05-2026-epidemic-of-ebola-disease-in-the-democratic-republic-of-the-congo-and-uganda-determined-a-public-health-emergency-of-international-concern">Epidemic determined a public health emergency of international concern</a>. May 17, 2026.</li><li>World Health Organization. <a href="https://www.who.int/publications/i/item/B09772">Emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo outbreaks</a>. May 28, 2026 <em>(WHO’s guidance, not a study finding)</em>.</li><li>ECDC. <a href="https://www.ecdc.europa.eu/en/public-health-events/2026-eip-00026/2026-11-16">Ebola disease: Multi-country outbreak 2026 (epidemiological update)</a>. Nov. 16, 2026 <em>(trial launch in Congo)</em>.</li><li>UKHSA. <a href="https://www.gov.uk/government/publications/outbreaks-under-monitoring-in-2026/outbreaks-under-monitoring-week-39-week-ending-27-september-2026">Outbreaks under monitoring: week 39</a>. September 2026 <em>(largest recorded Bundibugyo outbreak)</em>.</li></ul><p><br></p><p><strong>The fine print</strong></p><ul><li>The first study measured antibody binding only. It had no comparison group, couldn’t verify who was vaccinated, and more than a third of people in one city dropped out over five years.</li><li>The second study used a different vaccine, trial volunteers, a stand-in virus rather than live virus, and in some groups a short gap between doses that the authors say may have limited cross-reactions. It was funded by the vaccine’s manufacturer.</li><li>What would settle it: trials that compare vaccinated and unvaccinated people and track who gets sick, plus tests of whether antibodies neutralize the actual virus.</li><li>Outbreak numbers change by the week. Check the CDC page for current figures.</li></ul><p><br></p><p><strong>Credits</strong></p><ul><li><strong>Hosts:</strong> Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs).</li><li><strong>Outro music:</strong> created with Eleven Music.</li><li><strong>Website:</strong> frompeertoear.com</li><li><strong>Contact and corrections:</strong> frompeertoear@gmail.com. If we got something wrong, tell us and we’ll fix it here.</li></ul><p><br></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>A licensed Ebola vaccine exists. The outbreak now spreading through Congo is caused by a different Ebola virus, and no vaccine is licensed for it. Can the first one help against the second?</p><p><br></p><p>In this episode, Emma and Ezra look at two peer-reviewed studies. A 2026 study in The Lancet by Halbrook, Rimoin, and colleagues followed just over a thousand people in Congo who received the licensed vaccine, and found antibodies that bind to a Bundibugyo virus protein, in different patterns in two cities. A 2025 study in Science Translational Medicine by Mdluli, Rolland, and colleagues tested a different vaccine and found essentially no meaningful binding to that protein. Both measure antibodies in blood, not whether anyone is protected. Along the way: why “sticking” isn’t “blocking,” what an optimist and a realist each take from the data, and the comparison that would settle it.</p><p><br></p><p>This episode is about research, not medical advice.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><br></p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> some vaccinated people in Congo had antibodies that bound to a Bundibugyo protein, in different patterns in two cities, while a second study of a different vaccine found essentially no meaningful binding.</li><li><strong>What they can’t tell us:</strong> whether any vaccine protects anyone against Bundibugyo. Both studies measure antibodies in blood, not illness, and the first has no unvaccinated comparison group.</li><li><strong>A question for any headline:</strong> are they measuring antibodies, or measuring illness?</li></ul><p><br></p><p><strong>For practitioners and policymakers</strong></p><ul><li>Antibody reactivity on a blood test is not a protection test. What answers the question is a comparison group, followed for infection, plus tests of whether antibodies can neutralize the actual virus.</li><li>A neutral question to ask of any proposal: will anyone track the outcomes, and is there a group to compare against?</li><li>A trial that includes the licensed vaccine started in Congo in October; the studies here can’t say what it will find.</li><li>This episode is research, not medical advice, and it makes no recommendation about who should or shouldn’t be vaccinated.</li></ul><p><br></p><p><strong>The research</strong></p><p><em>Primary paper (licensed vaccine, Congo).</em> Halbrook, M., Merritt, S., Hoff, N. A., Mukadi, P., Kompany, J. P., Musene, K., … Rimoin, A. W. (2026). Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus–Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: A longitudinal cohort study. The Lancet, 408(10559), 1019–1028. <a href="https://doi.org/10.1016/S0140-6736(26)01608-9">https://doi.org/10.1016/S0140-6736(26)01608-9</a></p><ul><li><strong>Access:</strong> open access.</li><li><strong>Found:</strong> antibodies that bind to a Bundibugyo protein appeared in about half of vaccinated people in Beni and in about one in three in Mbandaka at one later visit, and the patterns differed. Limit: it measured binding only, with no unvaccinated comparison group, so it can’t say the vaccine caused the pattern or protects.</li></ul><p><br></p><p><em>Companion paper (a different vaccine, trial volunteers).</em> Mdluli, T., Wollen-Roberts, S., Merbah, M., … Rolland, M. (2025). Ebola virus vaccination elicits Ebola virus–specific immune responses without substantial cross-reactivity to other filoviruses. Science Translational Medicine, 17(792), Article eadq2496. <a href="https://doi.org/10.1126/scitranslmed.adq2496">https://doi.org/10.1126/scitranslmed.adq2496</a></p><ul><li><strong>Access:</strong> closed access (subscription or library login). We didn’t find a legal free version; the abstract is indexed in PubMed (PMID 40173257).</li><li><strong>Found:</strong> after two doses of Janssen’s Ebola vaccine, antibodies were mostly specific to the Zaire protein, with essentially no meaningful binding to Bundibugyo. Limit: a different vaccine and lab method, trial volunteers rather than outbreak-affected communities, and funding from the vaccine’s manufacturer.</li></ul><p><br></p><p>The two studies use different vaccines, people, and lab methods, so their numbers shouldn’t be compared side by side.</p><p><br></p><p><strong>In the news</strong></p><ul><li>CDC. <a href="https://www.cdc.gov/ebola/situation-summary/index.html">Ebola Outbreak: Key Facts (situation summary)</a>. Counts as of Nov. 17, 2026 (updated Nov. 19, 2026); they change weekly.</li><li>World Health Organization. <a href="https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON602">Outbreak notice 2026-DON602</a>. May 2026.</li><li>World Health Organization. <a href="https://www.who.int/news/item/17-05-2026-epidemic-of-ebola-disease-in-the-democratic-republic-of-the-congo-and-uganda-determined-a-public-health-emergency-of-international-concern">Epidemic determined a public health emergency of international concern</a>. May 17, 2026.</li><li>World Health Organization. <a href="https://www.who.int/publications/i/item/B09772">Emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo outbreaks</a>. May 28, 2026 <em>(WHO’s guidance, not a study finding)</em>.</li><li>ECDC. <a href="https://www.ecdc.europa.eu/en/public-health-events/2026-eip-00026/2026-11-16">Ebola disease: Multi-country outbreak 2026 (epidemiological update)</a>. Nov. 16, 2026 <em>(trial launch in Congo)</em>.</li><li>UKHSA. <a href="https://www.gov.uk/government/publications/outbreaks-under-monitoring-in-2026/outbreaks-under-monitoring-week-39-week-ending-27-september-2026">Outbreaks under monitoring: week 39</a>. September 2026 <em>(largest recorded Bundibugyo outbreak)</em>.</li></ul><p><br></p><p><strong>The fine print</strong></p><ul><li>The first study measured antibody binding only. It had no comparison group, couldn’t verify who was vaccinated, and more than a third of people in one city dropped out over five years.</li><li>The second study used a different vaccine, trial volunteers, a stand-in virus rather than live virus, and in some groups a short gap between doses that the authors say may have limited cross-reactions. It was funded by the vaccine’s manufacturer.</li><li>What would settle it: trials that compare vaccinated and unvaccinated people and track who gets sick, plus tests of whether antibodies neutralize the actual virus.</li><li>Outbreak numbers change by the week. Check the CDC page for current figures.</li></ul><p><br></p><p><strong>Credits</strong></p><ul><li><strong>Hosts:</strong> Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs).</li><li><strong>Outro music:</strong> created with Eleven Music.</li><li><strong>Website:</strong> frompeertoear.com</li><li><strong>Contact and corrections:</strong> frompeertoear@gmail.com. If we got something wrong, tell us and we’ll fix it here.</li></ul><p><br></p>]]>
      </content:encoded>
      <pubDate>Thu, 19 Nov 2026 12:24:01 -0800</pubDate>
      <author>From Peer to Ear</author>
      <enclosure url="https://media.transistor.fm/8a0aeca7/eedaf679.mp3" length="14296486" type="audio/mpeg"/>
      <itunes:author>From Peer to Ear</itunes:author>
      <itunes:duration>595</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>A licensed Ebola vaccine exists. The outbreak now spreading through Congo is caused by a different Ebola virus, and no vaccine is licensed for it. Can the first one help against the second?</p><p><br></p><p>In this episode, Emma and Ezra look at two peer-reviewed studies. A 2026 study in The Lancet by Halbrook, Rimoin, and colleagues followed just over a thousand people in Congo who received the licensed vaccine, and found antibodies that bind to a Bundibugyo virus protein, in different patterns in two cities. A 2025 study in Science Translational Medicine by Mdluli, Rolland, and colleagues tested a different vaccine and found essentially no meaningful binding to that protein. Both measure antibodies in blood, not whether anyone is protected. Along the way: why “sticking” isn’t “blocking,” what an optimist and a realist each take from the data, and the comparison that would settle it.</p><p><br></p><p>This episode is about research, not medical advice.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><br></p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> some vaccinated people in Congo had antibodies that bound to a Bundibugyo protein, in different patterns in two cities, while a second study of a different vaccine found essentially no meaningful binding.</li><li><strong>What they can’t tell us:</strong> whether any vaccine protects anyone against Bundibugyo. Both studies measure antibodies in blood, not illness, and the first has no unvaccinated comparison group.</li><li><strong>A question for any headline:</strong> are they measuring antibodies, or measuring illness?</li></ul><p><br></p><p><strong>For practitioners and policymakers</strong></p><ul><li>Antibody reactivity on a blood test is not a protection test. What answers the question is a comparison group, followed for infection, plus tests of whether antibodies can neutralize the actual virus.</li><li>A neutral question to ask of any proposal: will anyone track the outcomes, and is there a group to compare against?</li><li>A trial that includes the licensed vaccine started in Congo in October; the studies here can’t say what it will find.</li><li>This episode is research, not medical advice, and it makes no recommendation about who should or shouldn’t be vaccinated.</li></ul><p><br></p><p><strong>The research</strong></p><p><em>Primary paper (licensed vaccine, Congo).</em> Halbrook, M., Merritt, S., Hoff, N. A., Mukadi, P., Kompany, J. P., Musene, K., … Rimoin, A. W. (2026). Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus–Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: A longitudinal cohort study. The Lancet, 408(10559), 1019–1028. <a href="https://doi.org/10.1016/S0140-6736(26)01608-9">https://doi.org/10.1016/S0140-6736(26)01608-9</a></p><ul><li><strong>Access:</strong> open access.</li><li><strong>Found:</strong> antibodies that bind to a Bundibugyo protein appeared in about half of vaccinated people in Beni and in about one in three in Mbandaka at one later visit, and the patterns differed. Limit: it measured binding only, with no unvaccinated comparison group, so it can’t say the vaccine caused the pattern or protects.</li></ul><p><br></p><p><em>Companion paper (a different vaccine, trial volunteers).</em> Mdluli, T., Wollen-Roberts, S., Merbah, M., … Rolland, M. (2025). Ebola virus vaccination elicits Ebola virus–specific immune responses without substantial cross-reactivity to other filoviruses. Science Translational Medicine, 17(792), Article eadq2496. <a href="https://doi.org/10.1126/scitranslmed.adq2496">https://doi.org/10.1126/scitranslmed.adq2496</a></p><ul><li><strong>Access:</strong> closed access (subscription or library login). We didn’t find a legal free version; the abstract is indexed in PubMed (PMID 40173257).</li><li><strong>Found:</strong> after two doses of Janssen’s Ebola vaccine, antibodies were mostly specific to the Zaire protein, with essentially no meaningful binding to Bundibugyo. Limit: a different vaccine and lab method, trial volunteers rather than outbreak-affected communities, and funding from the vaccine’s manufacturer.</li></ul><p><br></p><p>The two studies use different vaccines, people, and lab methods, so their numbers shouldn’t be compared side by side.</p><p><br></p><p><strong>In the news</strong></p><ul><li>CDC. <a href="https://www.cdc.gov/ebola/situation-summary/index.html">Ebola Outbreak: Key Facts (situation summary)</a>. Counts as of Nov. 17, 2026 (updated Nov. 19, 2026); they change weekly.</li><li>World Health Organization. <a href="https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON602">Outbreak notice 2026-DON602</a>. May 2026.</li><li>World Health Organization. <a href="https://www.who.int/news/item/17-05-2026-epidemic-of-ebola-disease-in-the-democratic-republic-of-the-congo-and-uganda-determined-a-public-health-emergency-of-international-concern">Epidemic determined a public health emergency of international concern</a>. May 17, 2026.</li><li>World Health Organization. <a href="https://www.who.int/publications/i/item/B09772">Emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo outbreaks</a>. May 28, 2026 <em>(WHO’s guidance, not a study finding)</em>.</li><li>ECDC. <a href="https://www.ecdc.europa.eu/en/public-health-events/2026-eip-00026/2026-11-16">Ebola disease: Multi-country outbreak 2026 (epidemiological update)</a>. Nov. 16, 2026 <em>(trial launch in Congo)</em>.</li><li>UKHSA. <a href="https://www.gov.uk/government/publications/outbreaks-under-monitoring-in-2026/outbreaks-under-monitoring-week-39-week-ending-27-september-2026">Outbreaks under monitoring: week 39</a>. September 2026 <em>(largest recorded Bundibugyo outbreak)</em>.</li></ul><p><br></p><p><strong>The fine print</strong></p><ul><li>The first study measured antibody binding only. It had no comparison group, couldn’t verify who was vaccinated, and more than a third of people in one city dropped out over five years.</li><li>The second study used a different vaccine, trial volunteers, a stand-in virus rather than live virus, and in some groups a short gap between doses that the authors say may have limited cross-reactions. It was funded by the vaccine’s manufacturer.</li><li>What would settle it: trials that compare vaccinated and unvaccinated people and track who gets sick, plus tests of whether antibodies neutralize the actual virus.</li><li>Outbreak numbers change by the week. Check the CDC page for current figures.</li></ul><p><br></p><p><strong>Credits</strong></p><ul><li><strong>Hosts:</strong> Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs).</li><li><strong>Outro music:</strong> created with Eleven Music.</li><li><strong>Website:</strong> frompeertoear.com</li><li><strong>Contact and corrections:</strong> frompeertoear@gmail.com. If we got something wrong, tell us and we’ll fix it here.</li></ul><p><br></p>]]>
      </itunes:summary>
      <itunes:keywords>research, peer-reviewed, biology, Ebola, Bundibugyo, vaccines, Ervebo, outbreak, evidence-based, science communication</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Counting CTE in Former NFL Players</title>
      <itunes:episode>4</itunes:episode>
      <podcast:episode>4</podcast:episode>
      <itunes:title>Counting CTE in Former NFL Players</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">4bec25b5-06b7-4f28-85d1-10bd812d1df1</guid>
      <link>https://share.transistor.fm/s/86f58226</link>
      <description>
        <![CDATA[<p>Two studies this year asked how common the brain disease CTE is among former NFL players, and they counted in very different ways. CTE can only be definitively diagnosed after death, so the hard part is deciding who gets counted.</p><p>In this episode, Emma and Ezra look at a 2026 study in JAMA Network Open by Gallini and colleagues, and a 2026 study in the BMJ by Daneshvar and colleagues. Both study deceased players, with brain findings from autopsy, so they show links, not causes. The first adjusts for the fact that families of players with symptoms may be more likely to donate a brain, and estimates that roughly three in four deceased former players had CTE at death. The second refuses to guess about players who didn't donate and reports a range, with a minimum of nearly one in four for players who died from 2016 to 2021. Along the way: why the two studies aren't fully independent, the difference between "went with" and "caused," and three questions worth asking of any claim.</p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> CTE was common in the brains of deceased former NFL players, even after the studies took the donation problem seriously.</li><li><strong>What they can't tell us:</strong> how common CTE is among living players, current players, or college, high school and youth players, and what causes it. Both studies find links in autopsy data.</li><li><strong>A question for any claim:</strong> who was counted, and who is missing?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>When you see a big percentage about CTE, check who was counted. These studies are about deceased former NFL players.</li><li>CTE can't be diagnosed in a living person, and the BMJ study found death certificates often miss dementia, so records alone undercount it.</li><li>Rules of thumb (ours, not the papers') for judging any claim or proposal: who is being counted and who is missing, is there a comparison group, and will anyone track the results?</li><li>The episode makes no recommendation about football rules, the NFL, or any policy.</li></ul><p><strong>The research</strong></p><ul><li><strong>Primary paper (open access):</strong> Gallini, J., Alosco, M. L., Abdolmohammadi, B., Weuve, J., McKee, A. C., Stein, T. D., Stern, R. A., Daneshvar, D. H., Mez, J., Nowinski, C., &amp; Tripodis, Y. (2026). Bias-adjusted prevalence of chronic traumatic encephalopathy among deceased National Football League players. JAMA Network Open, 9(10), Article e2640884. <a href="https://doi.org/10.1001/jamanetworkopen.2026.40884">https://doi.org/10.1001/jamanetworkopen.2026.40884</a><br>Found: after adjusting for who donates brains, an estimated three in four deceased former NFL players had CTE at death. Limit: it is a modeled estimate that rests on a stand-in for cognitive symptoms in players who didn't donate, and it applies only to deceased NFL players. Corresponding author: Yorghos Tripodis, Boston University School of Public Health.</li><li><strong>Companion paper (open access):</strong> Daneshvar, D. H., Nowinski, C. J., Abdolmohammadi, B., Luster, C. B., Uretsky, M., Martin, B. M., Palmisano, J. N., Weuve, J., McClean, M. D., Cherry, J. D., Dwyer, B., Feigel, E. D., Mastrodicasa, M. J., Alvarez, V. E., Rabinovici, G. D., Seeley, W. W., Grinberg, L. T., Crary, J. F., Stein, T. D., . . . Mez, J. (2026). Prevalence of chronic traumatic encephalopathy at death in National Football League players: Retrospective population based cohort study, 2008-21. BMJ, 394, Article e100418. <a href="https://doi.org/10.1136/bmj-2026-100418">https://doi.org/10.1136/bmj-2026-100418</a><br>Found: without assuming anything about players who didn't donate, at minimum nearly a quarter of former NFL players who died in 2016-21 had CTE, and the true share could be much higher. Among donors, the most severe stage of CTE went with higher dementia risk. Limit: the range is wide, and the study finds links, not causes. Corresponding author: Daniel H. Daneshvar, Mass General Brigham.</li></ul><p>Both papers draw largely on the same brain bank (UNITE, Boston University) and share several authors, so they are not independent datasets.</p><p><br><strong>In the news</strong></p><ul><li>BMJ. <a href="https://www.bmj.com/content/394/bmj-2026-100418">Prevalence of chronic traumatic encephalopathy at death in National Football League players</a>. Aug. 25, 2026. (The study.)</li><li>JAMA Network Open. <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2855918">Bias-Adjusted Prevalence of Chronic Traumatic Encephalopathy Among Deceased National Football League Players</a>. Oct. 28, 2026. (The study.)</li><li>NPR (via St. Louis Public Radio). <a href="https://www.stlpr.org/npr/2026-08-25/at-least-25-of-former-nfl-players-who-died-between-2016-and-2021-had-cte-study-finds">At least 25% of former NFL players who died between 2016 and 2021 had CTE, study finds</a>. Aug. 25, 2026.</li><li>Fox 29 Philadelphia. <a href="https://www.fox29.com/sports/study-deceased-nfl-players-cte">New study says roughly 3 in 4 deceased NFL players from 2008 to 2023 had CTE</a>. Oct. 29, 2026.</li><li>Healio. <a href="https://www.healio.com/news/neurology/20261105/75-of-nfl-players-estimated-to-have-cte-at-death-after-adjusting-for-selection-bias">75% of NFL players estimated to have CTE at death after adjusting for selection bias</a>. Nov. 5, 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>Both studies cover deceased players, with brain findings from autopsy. They find links, not causes, and can't speak for living players, current players, or college, high school and youth players.</li><li>The donation problem is addressed, not erased. Neither paper can fully account for who died earlier, which shapes who is left to count.</li><li>Several authors disclose funding and ties, including travel support from the league, funding linked to the players' union, and a foundation. Both papers say the funders had no role in design or analysis. See each paper's disclosures.</li><li>What would help: studies that follow people for years while they're alive, then examine their brains afterward.</li></ul><p><strong>Credits and links</strong></p><ul><li>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music: created with Eleven Music.</li><li>Website: <a href="https://frompeertoear.com">frompeertoear.com</a></li><li>Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it here.</li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Two studies this year asked how common the brain disease CTE is among former NFL players, and they counted in very different ways. CTE can only be definitively diagnosed after death, so the hard part is deciding who gets counted.</p><p>In this episode, Emma and Ezra look at a 2026 study in JAMA Network Open by Gallini and colleagues, and a 2026 study in the BMJ by Daneshvar and colleagues. Both study deceased players, with brain findings from autopsy, so they show links, not causes. The first adjusts for the fact that families of players with symptoms may be more likely to donate a brain, and estimates that roughly three in four deceased former players had CTE at death. The second refuses to guess about players who didn't donate and reports a range, with a minimum of nearly one in four for players who died from 2016 to 2021. Along the way: why the two studies aren't fully independent, the difference between "went with" and "caused," and three questions worth asking of any claim.</p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> CTE was common in the brains of deceased former NFL players, even after the studies took the donation problem seriously.</li><li><strong>What they can't tell us:</strong> how common CTE is among living players, current players, or college, high school and youth players, and what causes it. Both studies find links in autopsy data.</li><li><strong>A question for any claim:</strong> who was counted, and who is missing?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>When you see a big percentage about CTE, check who was counted. These studies are about deceased former NFL players.</li><li>CTE can't be diagnosed in a living person, and the BMJ study found death certificates often miss dementia, so records alone undercount it.</li><li>Rules of thumb (ours, not the papers') for judging any claim or proposal: who is being counted and who is missing, is there a comparison group, and will anyone track the results?</li><li>The episode makes no recommendation about football rules, the NFL, or any policy.</li></ul><p><strong>The research</strong></p><ul><li><strong>Primary paper (open access):</strong> Gallini, J., Alosco, M. L., Abdolmohammadi, B., Weuve, J., McKee, A. C., Stein, T. D., Stern, R. A., Daneshvar, D. H., Mez, J., Nowinski, C., &amp; Tripodis, Y. (2026). Bias-adjusted prevalence of chronic traumatic encephalopathy among deceased National Football League players. JAMA Network Open, 9(10), Article e2640884. <a href="https://doi.org/10.1001/jamanetworkopen.2026.40884">https://doi.org/10.1001/jamanetworkopen.2026.40884</a><br>Found: after adjusting for who donates brains, an estimated three in four deceased former NFL players had CTE at death. Limit: it is a modeled estimate that rests on a stand-in for cognitive symptoms in players who didn't donate, and it applies only to deceased NFL players. Corresponding author: Yorghos Tripodis, Boston University School of Public Health.</li><li><strong>Companion paper (open access):</strong> Daneshvar, D. H., Nowinski, C. J., Abdolmohammadi, B., Luster, C. B., Uretsky, M., Martin, B. M., Palmisano, J. N., Weuve, J., McClean, M. D., Cherry, J. D., Dwyer, B., Feigel, E. D., Mastrodicasa, M. J., Alvarez, V. E., Rabinovici, G. D., Seeley, W. W., Grinberg, L. T., Crary, J. F., Stein, T. D., . . . Mez, J. (2026). Prevalence of chronic traumatic encephalopathy at death in National Football League players: Retrospective population based cohort study, 2008-21. BMJ, 394, Article e100418. <a href="https://doi.org/10.1136/bmj-2026-100418">https://doi.org/10.1136/bmj-2026-100418</a><br>Found: without assuming anything about players who didn't donate, at minimum nearly a quarter of former NFL players who died in 2016-21 had CTE, and the true share could be much higher. Among donors, the most severe stage of CTE went with higher dementia risk. Limit: the range is wide, and the study finds links, not causes. Corresponding author: Daniel H. Daneshvar, Mass General Brigham.</li></ul><p>Both papers draw largely on the same brain bank (UNITE, Boston University) and share several authors, so they are not independent datasets.</p><p><br><strong>In the news</strong></p><ul><li>BMJ. <a href="https://www.bmj.com/content/394/bmj-2026-100418">Prevalence of chronic traumatic encephalopathy at death in National Football League players</a>. Aug. 25, 2026. (The study.)</li><li>JAMA Network Open. <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2855918">Bias-Adjusted Prevalence of Chronic Traumatic Encephalopathy Among Deceased National Football League Players</a>. Oct. 28, 2026. (The study.)</li><li>NPR (via St. Louis Public Radio). <a href="https://www.stlpr.org/npr/2026-08-25/at-least-25-of-former-nfl-players-who-died-between-2016-and-2021-had-cte-study-finds">At least 25% of former NFL players who died between 2016 and 2021 had CTE, study finds</a>. Aug. 25, 2026.</li><li>Fox 29 Philadelphia. <a href="https://www.fox29.com/sports/study-deceased-nfl-players-cte">New study says roughly 3 in 4 deceased NFL players from 2008 to 2023 had CTE</a>. Oct. 29, 2026.</li><li>Healio. <a href="https://www.healio.com/news/neurology/20261105/75-of-nfl-players-estimated-to-have-cte-at-death-after-adjusting-for-selection-bias">75% of NFL players estimated to have CTE at death after adjusting for selection bias</a>. Nov. 5, 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>Both studies cover deceased players, with brain findings from autopsy. They find links, not causes, and can't speak for living players, current players, or college, high school and youth players.</li><li>The donation problem is addressed, not erased. Neither paper can fully account for who died earlier, which shapes who is left to count.</li><li>Several authors disclose funding and ties, including travel support from the league, funding linked to the players' union, and a foundation. Both papers say the funders had no role in design or analysis. See each paper's disclosures.</li><li>What would help: studies that follow people for years while they're alive, then examine their brains afterward.</li></ul><p><strong>Credits and links</strong></p><ul><li>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music: created with Eleven Music.</li><li>Website: <a href="https://frompeertoear.com">frompeertoear.com</a></li><li>Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it here.</li></ul>]]>
      </content:encoded>
      <pubDate>Tue, 17 Nov 2026 14:04:04 -0800</pubDate>
      <author>From Peer to Ear</author>
      <enclosure url="https://media.transistor.fm/86f58226/780fd282.mp3" length="13799340" type="audio/mpeg"/>
      <itunes:author>From Peer to Ear</itunes:author>
      <itunes:duration>574</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>Two studies this year asked how common the brain disease CTE is among former NFL players, and they counted in very different ways. CTE can only be definitively diagnosed after death, so the hard part is deciding who gets counted.</p><p>In this episode, Emma and Ezra look at a 2026 study in JAMA Network Open by Gallini and colleagues, and a 2026 study in the BMJ by Daneshvar and colleagues. Both study deceased players, with brain findings from autopsy, so they show links, not causes. The first adjusts for the fact that families of players with symptoms may be more likely to donate a brain, and estimates that roughly three in four deceased former players had CTE at death. The second refuses to guess about players who didn't donate and reports a range, with a minimum of nearly one in four for players who died from 2016 to 2021. Along the way: why the two studies aren't fully independent, the difference between "went with" and "caused," and three questions worth asking of any claim.</p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> CTE was common in the brains of deceased former NFL players, even after the studies took the donation problem seriously.</li><li><strong>What they can't tell us:</strong> how common CTE is among living players, current players, or college, high school and youth players, and what causes it. Both studies find links in autopsy data.</li><li><strong>A question for any claim:</strong> who was counted, and who is missing?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>When you see a big percentage about CTE, check who was counted. These studies are about deceased former NFL players.</li><li>CTE can't be diagnosed in a living person, and the BMJ study found death certificates often miss dementia, so records alone undercount it.</li><li>Rules of thumb (ours, not the papers') for judging any claim or proposal: who is being counted and who is missing, is there a comparison group, and will anyone track the results?</li><li>The episode makes no recommendation about football rules, the NFL, or any policy.</li></ul><p><strong>The research</strong></p><ul><li><strong>Primary paper (open access):</strong> Gallini, J., Alosco, M. L., Abdolmohammadi, B., Weuve, J., McKee, A. C., Stein, T. D., Stern, R. A., Daneshvar, D. H., Mez, J., Nowinski, C., &amp; Tripodis, Y. (2026). Bias-adjusted prevalence of chronic traumatic encephalopathy among deceased National Football League players. JAMA Network Open, 9(10), Article e2640884. <a href="https://doi.org/10.1001/jamanetworkopen.2026.40884">https://doi.org/10.1001/jamanetworkopen.2026.40884</a><br>Found: after adjusting for who donates brains, an estimated three in four deceased former NFL players had CTE at death. Limit: it is a modeled estimate that rests on a stand-in for cognitive symptoms in players who didn't donate, and it applies only to deceased NFL players. Corresponding author: Yorghos Tripodis, Boston University School of Public Health.</li><li><strong>Companion paper (open access):</strong> Daneshvar, D. H., Nowinski, C. J., Abdolmohammadi, B., Luster, C. B., Uretsky, M., Martin, B. M., Palmisano, J. N., Weuve, J., McClean, M. D., Cherry, J. D., Dwyer, B., Feigel, E. D., Mastrodicasa, M. J., Alvarez, V. E., Rabinovici, G. D., Seeley, W. W., Grinberg, L. T., Crary, J. F., Stein, T. D., . . . Mez, J. (2026). Prevalence of chronic traumatic encephalopathy at death in National Football League players: Retrospective population based cohort study, 2008-21. BMJ, 394, Article e100418. <a href="https://doi.org/10.1136/bmj-2026-100418">https://doi.org/10.1136/bmj-2026-100418</a><br>Found: without assuming anything about players who didn't donate, at minimum nearly a quarter of former NFL players who died in 2016-21 had CTE, and the true share could be much higher. Among donors, the most severe stage of CTE went with higher dementia risk. Limit: the range is wide, and the study finds links, not causes. Corresponding author: Daniel H. Daneshvar, Mass General Brigham.</li></ul><p>Both papers draw largely on the same brain bank (UNITE, Boston University) and share several authors, so they are not independent datasets.</p><p><br><strong>In the news</strong></p><ul><li>BMJ. <a href="https://www.bmj.com/content/394/bmj-2026-100418">Prevalence of chronic traumatic encephalopathy at death in National Football League players</a>. Aug. 25, 2026. (The study.)</li><li>JAMA Network Open. <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2855918">Bias-Adjusted Prevalence of Chronic Traumatic Encephalopathy Among Deceased National Football League Players</a>. Oct. 28, 2026. (The study.)</li><li>NPR (via St. Louis Public Radio). <a href="https://www.stlpr.org/npr/2026-08-25/at-least-25-of-former-nfl-players-who-died-between-2016-and-2021-had-cte-study-finds">At least 25% of former NFL players who died between 2016 and 2021 had CTE, study finds</a>. Aug. 25, 2026.</li><li>Fox 29 Philadelphia. <a href="https://www.fox29.com/sports/study-deceased-nfl-players-cte">New study says roughly 3 in 4 deceased NFL players from 2008 to 2023 had CTE</a>. Oct. 29, 2026.</li><li>Healio. <a href="https://www.healio.com/news/neurology/20261105/75-of-nfl-players-estimated-to-have-cte-at-death-after-adjusting-for-selection-bias">75% of NFL players estimated to have CTE at death after adjusting for selection bias</a>. Nov. 5, 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>Both studies cover deceased players, with brain findings from autopsy. They find links, not causes, and can't speak for living players, current players, or college, high school and youth players.</li><li>The donation problem is addressed, not erased. Neither paper can fully account for who died earlier, which shapes who is left to count.</li><li>Several authors disclose funding and ties, including travel support from the league, funding linked to the players' union, and a foundation. Both papers say the funders had no role in design or analysis. See each paper's disclosures.</li><li>What would help: studies that follow people for years while they're alive, then examine their brains afterward.</li></ul><p><strong>Credits and links</strong></p><ul><li>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music: created with Eleven Music.</li><li>Website: <a href="https://frompeertoear.com">frompeertoear.com</a></li><li>Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it here.</li></ul>]]>
      </itunes:summary>
      <itunes:keywords>research, peer-reviewed, neuroscience, CTE, chronic traumatic encephalopathy, NFL, brain health, dementia, evidence-based, science communication</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Can an AI Companion Ease Loneliness?</title>
      <itunes:episode>3</itunes:episode>
      <podcast:episode>3</podcast:episode>
      <itunes:title>Can an AI Companion Ease Loneliness?</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">7875ad81-a4af-47ad-8173-684121327fcc</guid>
      <link>https://share.transistor.fm/s/9cfdf33a</link>
      <description>
        <![CDATA[<p>In late October, New York enacted a law limiting what AI companion chatbots can do with users under eighteen. Behind it sits a simpler question: do these chatbots make people less lonely, or more?</p><p><br></p><p>Emma and Ezra look at two peer-reviewed studies from the same research group. A year-long survey of more than two thousand adults found a small link between social chatbot use and later emotional isolation, though only on one of its two loneliness measures. A preregistered two-week experiment with first-semester university students found that texting a randomly paired fellow student left students less lonely than texting a supportive chatbot, which was not detectably different from journaling. The survey can't show cause, and neither study tested the law or was designed around minors.</p><p><br></p><p>Along the way: why "not detectably different" isn't "nothing," and one question to ask of any claim about chatbots and loneliness.</p><p><br></p><p>This episode doesn't take a side on the New York law or any other policy; it covers what the research found.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><br></p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> neither study found clear evidence that chatting with a chatbot eases loneliness over time. The experiment hinted that a chat can ease a bad mood in the moment, and contact with another person did more for loneliness.</li><li><strong>What they can't tell us:</strong> whether chatbots cause loneliness or lonely people simply use them more, and anything about teenagers or the New York law.</li><li><strong>A question for any claim:</strong> who was studied?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>The survey counted advice, small talk and companionship together. For teachers, counselors and anyone who works with lonely people, it may help to ask what a chatbot is actually doing for a person.</li><li>Neither study tested a law, and neither was designed to look at minors, so the New York law's under-eighteen question is outside what they can answer, either way.</li><li>Questions worth asking of any chatbot proposal: which people, what ages, compared with what, and will anyone track the results?</li></ul><p><strong>The research</strong></p><p><strong>Primary paper.</strong> Folk, D., &amp; Dunn, E. (2026). How does turning to AI for companionship predict loneliness and vice versa? <em>Psychological Science, 37</em>(4), 276–286. <a href="https://doi.org/10.1177/09567976261427747">https://doi.org/10.1177/09567976261427747</a> (open access). Found: in an exploratory survey of more than two thousand adults over a year, people who increased their chatbot use reported more emotional isolation four months later, and lonelier people used chatbots more, but the links were small and appeared on one of two loneliness measures. Limit: observational and not preregistered, so it can't show cause. Corresponding author: Dunigan Folk.</p><p><br></p><p><strong>Companion paper.</strong> Li, R.-N., Folk, D., Singh, A., Ungar, L., &amp; Dunn, E. (2026). Is a random human peer better than a highly supportive chatbot in reducing loneliness over time? <em>Journal of Experimental Social Psychology, 125</em>, Article 104911. <a href="https://doi.org/10.1016/j.jesp.2026.104911">https://doi.org/10.1016/j.jesp.2026.104911</a> (open access). Found: in a preregistered two-week experiment with first-semester students, those paired with a human peer ended up less lonely than both the journaling group and the chatbot group, and the chatbot group was not detectably different from journaling. Limit: short, one chatbot, one university, and the human pairs had met briefly in person first. Corresponding author: Ruo-Ning Li.</p><p><br></p><p>Both papers come from the same research group, so they are related, not independent.</p><p><br></p><p><strong>In the news</strong></p><ul><li>Office of Governor Kathy Hochul. <a href="https://www.governor.ny.gov/news/governor-hochul-signs-nation-leading-legislation-protect-kids-ai-chatbots-and-ensure-baby">Governor Hochul Signs Nation-Leading Legislation to Protect Kids From AI Chatbots and to Ensure Baby Monitor Safety</a>. Oct. 28, 2026. (Government release.)</li><li>Associated Press (via ClickOrlando). <a href="https://clickorlando.com/business/2026/10/28/new-york-enacts-ban-on-unsafe-chatbot-behavior-with-kids-as-states-push-ai-regulation-boundaries">New York enacts ban on 'unsafe' chatbot behavior with kids as states push AI regulation boundaries</a>. Oct. 28, 2026.</li><li>New York State Senate. <a href="https://legislation.nysenate.gov/pdf/bills/2025/S9051B">S9051B bill text: Prohibition on Unsafe AI Companion Features for Minors</a>. Signed Oct. 28, 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>Neither study was designed around minors: the survey covered adults on an online panel, and the experiment covered first-year students averaging about eighteen.</li><li>The survey can't show cause. The experiment was preregistered, but it lasted two weeks, used one chatbot with one set of instructions, and the human pairs had met briefly in person first. The most common answer at the start was "rarely lonely."</li><li>Both papers come from the same research group, and neither reports a replication.</li><li>The mood finding in the experiment was exploratory.</li></ul><p><strong>Credits</strong></p><p>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music: created with Eleven Music. Website: frompeertoear.com. Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it here.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In late October, New York enacted a law limiting what AI companion chatbots can do with users under eighteen. Behind it sits a simpler question: do these chatbots make people less lonely, or more?</p><p><br></p><p>Emma and Ezra look at two peer-reviewed studies from the same research group. A year-long survey of more than two thousand adults found a small link between social chatbot use and later emotional isolation, though only on one of its two loneliness measures. A preregistered two-week experiment with first-semester university students found that texting a randomly paired fellow student left students less lonely than texting a supportive chatbot, which was not detectably different from journaling. The survey can't show cause, and neither study tested the law or was designed around minors.</p><p><br></p><p>Along the way: why "not detectably different" isn't "nothing," and one question to ask of any claim about chatbots and loneliness.</p><p><br></p><p>This episode doesn't take a side on the New York law or any other policy; it covers what the research found.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><br></p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> neither study found clear evidence that chatting with a chatbot eases loneliness over time. The experiment hinted that a chat can ease a bad mood in the moment, and contact with another person did more for loneliness.</li><li><strong>What they can't tell us:</strong> whether chatbots cause loneliness or lonely people simply use them more, and anything about teenagers or the New York law.</li><li><strong>A question for any claim:</strong> who was studied?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>The survey counted advice, small talk and companionship together. For teachers, counselors and anyone who works with lonely people, it may help to ask what a chatbot is actually doing for a person.</li><li>Neither study tested a law, and neither was designed to look at minors, so the New York law's under-eighteen question is outside what they can answer, either way.</li><li>Questions worth asking of any chatbot proposal: which people, what ages, compared with what, and will anyone track the results?</li></ul><p><strong>The research</strong></p><p><strong>Primary paper.</strong> Folk, D., &amp; Dunn, E. (2026). How does turning to AI for companionship predict loneliness and vice versa? <em>Psychological Science, 37</em>(4), 276–286. <a href="https://doi.org/10.1177/09567976261427747">https://doi.org/10.1177/09567976261427747</a> (open access). Found: in an exploratory survey of more than two thousand adults over a year, people who increased their chatbot use reported more emotional isolation four months later, and lonelier people used chatbots more, but the links were small and appeared on one of two loneliness measures. Limit: observational and not preregistered, so it can't show cause. Corresponding author: Dunigan Folk.</p><p><br></p><p><strong>Companion paper.</strong> Li, R.-N., Folk, D., Singh, A., Ungar, L., &amp; Dunn, E. (2026). Is a random human peer better than a highly supportive chatbot in reducing loneliness over time? <em>Journal of Experimental Social Psychology, 125</em>, Article 104911. <a href="https://doi.org/10.1016/j.jesp.2026.104911">https://doi.org/10.1016/j.jesp.2026.104911</a> (open access). Found: in a preregistered two-week experiment with first-semester students, those paired with a human peer ended up less lonely than both the journaling group and the chatbot group, and the chatbot group was not detectably different from journaling. Limit: short, one chatbot, one university, and the human pairs had met briefly in person first. Corresponding author: Ruo-Ning Li.</p><p><br></p><p>Both papers come from the same research group, so they are related, not independent.</p><p><br></p><p><strong>In the news</strong></p><ul><li>Office of Governor Kathy Hochul. <a href="https://www.governor.ny.gov/news/governor-hochul-signs-nation-leading-legislation-protect-kids-ai-chatbots-and-ensure-baby">Governor Hochul Signs Nation-Leading Legislation to Protect Kids From AI Chatbots and to Ensure Baby Monitor Safety</a>. Oct. 28, 2026. (Government release.)</li><li>Associated Press (via ClickOrlando). <a href="https://clickorlando.com/business/2026/10/28/new-york-enacts-ban-on-unsafe-chatbot-behavior-with-kids-as-states-push-ai-regulation-boundaries">New York enacts ban on 'unsafe' chatbot behavior with kids as states push AI regulation boundaries</a>. Oct. 28, 2026.</li><li>New York State Senate. <a href="https://legislation.nysenate.gov/pdf/bills/2025/S9051B">S9051B bill text: Prohibition on Unsafe AI Companion Features for Minors</a>. Signed Oct. 28, 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>Neither study was designed around minors: the survey covered adults on an online panel, and the experiment covered first-year students averaging about eighteen.</li><li>The survey can't show cause. The experiment was preregistered, but it lasted two weeks, used one chatbot with one set of instructions, and the human pairs had met briefly in person first. The most common answer at the start was "rarely lonely."</li><li>Both papers come from the same research group, and neither reports a replication.</li><li>The mood finding in the experiment was exploratory.</li></ul><p><strong>Credits</strong></p><p>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music: created with Eleven Music. Website: frompeertoear.com. Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it here.</p>]]>
      </content:encoded>
      <pubDate>Tue, 17 Nov 2026 10:45:47 -0800</pubDate>
      <author>From Peer to Ear</author>
      <enclosure url="https://media.transistor.fm/9cfdf33a/9c65fe65.mp3" length="13994952" type="audio/mpeg"/>
      <itunes:author>From Peer to Ear</itunes:author>
      <itunes:duration>582</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In late October, New York enacted a law limiting what AI companion chatbots can do with users under eighteen. Behind it sits a simpler question: do these chatbots make people less lonely, or more?</p><p><br></p><p>Emma and Ezra look at two peer-reviewed studies from the same research group. A year-long survey of more than two thousand adults found a small link between social chatbot use and later emotional isolation, though only on one of its two loneliness measures. A preregistered two-week experiment with first-semester university students found that texting a randomly paired fellow student left students less lonely than texting a supportive chatbot, which was not detectably different from journaling. The survey can't show cause, and neither study tested the law or was designed around minors.</p><p><br></p><p>Along the way: why "not detectably different" isn't "nothing," and one question to ask of any claim about chatbots and loneliness.</p><p><br></p><p>This episode doesn't take a side on the New York law or any other policy; it covers what the research found.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p><p><br></p><p><strong>What to take away</strong></p><ul><li><strong>What the studies support:</strong> neither study found clear evidence that chatting with a chatbot eases loneliness over time. The experiment hinted that a chat can ease a bad mood in the moment, and contact with another person did more for loneliness.</li><li><strong>What they can't tell us:</strong> whether chatbots cause loneliness or lonely people simply use them more, and anything about teenagers or the New York law.</li><li><strong>A question for any claim:</strong> who was studied?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>The survey counted advice, small talk and companionship together. For teachers, counselors and anyone who works with lonely people, it may help to ask what a chatbot is actually doing for a person.</li><li>Neither study tested a law, and neither was designed to look at minors, so the New York law's under-eighteen question is outside what they can answer, either way.</li><li>Questions worth asking of any chatbot proposal: which people, what ages, compared with what, and will anyone track the results?</li></ul><p><strong>The research</strong></p><p><strong>Primary paper.</strong> Folk, D., &amp; Dunn, E. (2026). How does turning to AI for companionship predict loneliness and vice versa? <em>Psychological Science, 37</em>(4), 276–286. <a href="https://doi.org/10.1177/09567976261427747">https://doi.org/10.1177/09567976261427747</a> (open access). Found: in an exploratory survey of more than two thousand adults over a year, people who increased their chatbot use reported more emotional isolation four months later, and lonelier people used chatbots more, but the links were small and appeared on one of two loneliness measures. Limit: observational and not preregistered, so it can't show cause. Corresponding author: Dunigan Folk.</p><p><br></p><p><strong>Companion paper.</strong> Li, R.-N., Folk, D., Singh, A., Ungar, L., &amp; Dunn, E. (2026). Is a random human peer better than a highly supportive chatbot in reducing loneliness over time? <em>Journal of Experimental Social Psychology, 125</em>, Article 104911. <a href="https://doi.org/10.1016/j.jesp.2026.104911">https://doi.org/10.1016/j.jesp.2026.104911</a> (open access). Found: in a preregistered two-week experiment with first-semester students, those paired with a human peer ended up less lonely than both the journaling group and the chatbot group, and the chatbot group was not detectably different from journaling. Limit: short, one chatbot, one university, and the human pairs had met briefly in person first. Corresponding author: Ruo-Ning Li.</p><p><br></p><p>Both papers come from the same research group, so they are related, not independent.</p><p><br></p><p><strong>In the news</strong></p><ul><li>Office of Governor Kathy Hochul. <a href="https://www.governor.ny.gov/news/governor-hochul-signs-nation-leading-legislation-protect-kids-ai-chatbots-and-ensure-baby">Governor Hochul Signs Nation-Leading Legislation to Protect Kids From AI Chatbots and to Ensure Baby Monitor Safety</a>. Oct. 28, 2026. (Government release.)</li><li>Associated Press (via ClickOrlando). <a href="https://clickorlando.com/business/2026/10/28/new-york-enacts-ban-on-unsafe-chatbot-behavior-with-kids-as-states-push-ai-regulation-boundaries">New York enacts ban on 'unsafe' chatbot behavior with kids as states push AI regulation boundaries</a>. Oct. 28, 2026.</li><li>New York State Senate. <a href="https://legislation.nysenate.gov/pdf/bills/2025/S9051B">S9051B bill text: Prohibition on Unsafe AI Companion Features for Minors</a>. Signed Oct. 28, 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>Neither study was designed around minors: the survey covered adults on an online panel, and the experiment covered first-year students averaging about eighteen.</li><li>The survey can't show cause. The experiment was preregistered, but it lasted two weeks, used one chatbot with one set of instructions, and the human pairs had met briefly in person first. The most common answer at the start was "rarely lonely."</li><li>Both papers come from the same research group, and neither reports a replication.</li><li>The mood finding in the experiment was exploratory.</li></ul><p><strong>Credits</strong></p><p>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music: created with Eleven Music. Website: frompeertoear.com. Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it here.</p>]]>
      </itunes:summary>
      <itunes:keywords>research, peer-reviewed, policy, psychology, loneliness, AI chatbots, AI companions, social connection, mental health, evidence-based, science communication</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Work Requirements in SNAP and Medicaid</title>
      <itunes:episode>2</itunes:episode>
      <podcast:episode>2</podcast:episode>
      <itunes:title>Work Requirements in SNAP and Medicaid</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">d0d7c029-ed33-4fa3-96fc-9608f86bf302</guid>
      <link>https://share.transistor.fm/s/db3a25bc</link>
      <description>
        <![CDATA[<p>Starting January 1, 2027, many adults on expansion Medicaid will have to document work, volunteering, or school to keep their coverage, and the federal rules for SNAP work requirements are being rewritten too. So what did researchers find when work requirements were actually tried? In Episode 2, Emma and Ezra look at two peer-reviewed studies.</p><p><br></p><p>The first followed Virginia SNAP participants when the state brought its work rule back in 2013, using a birthday cutoff at age fifty as a natural experiment: many more people left the program, and the study could not detect a gain in employment. The second looked at Georgia, the first state to attach work requirements to a Medicaid expansion: no clear change in coverage or employment against neighboring states, and coverage that lagged South Dakota, which expanded without a requirement. Along the way: why "no detectable gain" isn't "no gain," how turning fifty can work as an experiment, and three neutral questions to ask of any proposal.</p><p><br></p><p>This episode doesn't tell you what to think about these rules; it covers what the research found.</p><p><br></p><p><strong>What to take away</strong></p><ul><li>What the studies support: in Virginia, the SNAP work rule went with many more people leaving the program, and no detectable employment gain. In Georgia, Medicaid coverage did not clearly change against neighboring states, but lagged a state that expanded without a requirement.</li><li>What they can't tell us: what will happen to any one person, why people left, or how the new rules will play out. Neither study saw individual reasons for leaving.</li><li>A question for any proposal: compared to what? Is there a comparison group, and will anyone measure jobs and coverage, not just enrollment?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>If a rule changes, track who drops off and at which step. Neither study could see individual reasons, and that gap is visible from a front desk.</li><li>Three neutral questions for any proposal: Is there a comparison group? Will anyone measure jobs and coverage, not just enrollment? And for how long?</li><li>For the public: if rules change where you live, read your state agency's notices closely. The research doesn't yet say paperwork is the whole story.</li></ul><p><strong>The research</strong></p><ul><li>Gray, C., Leive, A., Prager, E., Pukelis, K., &amp; Zaki, M. (2023). Employed in a SNAP? The impact of work requirements on program participation and labor supply. American Economic Journal: Economic Policy, 15(1), 306–341. <a href="https://doi.org/10.1257/pol.20200561">https://doi.org/10.1257/pol.20200561</a> (The full article is behind the publisher's paywall. An earlier working paper is free from NBER: <a href="https://nber.org/papers/w28877">nber.org/papers/w28877</a>.)</li><li>Johnson, D. Y., Mein, S. A., Marinacci, L. X., Liu, M., &amp; Wadhera, R. K. (2025). Insurance coverage and employment after Medicaid expansion with work requirements: Quasi-experimental difference-in-differences study. BMJ, 390, e086792. <a href="https://doi.org/10.1136/bmj-2025-086792">https://doi.org/10.1136/bmj-2025-086792</a> (Open access.)</li></ul><p><strong>In the news</strong></p><ul><li>Courthouse News. <a href="https://courthousenews.com/judge-blocks-trump-administration-from-enforcing-new-medically-frail-medicaid-rule/">Judge blocks Trump administration from enforcing new "medically frail" Medicaid rule</a>. Oct. 29, 2026.</li><li>States Newsroom. <a href="https://www.newsfromthestates.com/node/435353">Judge strikes down Trump 'medical frailty' rule in Medicaid work requirements</a>. Oct. 29, 2026.</li><li>MPR News. <a href="https://www.mprnews.org/story/2026/10/30/judge-blocks-trump-administrations-medicaid-rule-forcing-sick-recipients-to-prove-frailty">Judge blocks Trump administration's Medicaid rule forcing sick recipients to prove frailty</a>. Oct. 30, 2026.</li><li>CBS Austin / TNND. <a href="https://cbsaustin.com/news/nation-world/federal-judge-blocks-trump-medicaid-work-rule-limits-on-medically-frail-exemptions">Federal judge blocks Trump Medicaid work-rule limits on 'medically frail' exemptions</a>. Late Oct. 2026.</li><li>Federal Register (public inspection). <a href="https://public-inspection.federalregister.gov/2026-22944.pdf">Modification to Work Requirements for Able-Bodied Adults</a> (USDA proposed rule, FNA-2025-0368). Filed Nov. 9; scheduled Nov. 10, 2026.</li><li>Stateline. <a href="https://stateline.org/2026/04/10/snap-work-requirements-dont-boost-jobs-but-drop-participation-research-finds/">SNAP work requirements don't boost jobs, but drop participation, research finds</a>. Apr. 10, 2026.</li><li>Stateline. <a href="https://stateline.org/2026/07/31/judge-rejects-states-bid-to-block-medicaid-work-rules/">Judge rejects states' bid to block Medicaid work rules</a>. Jul. 31, 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>The SNAP study is Virginia in the mid-2010s and is strongest for people near age fifty. The Medicaid study is one state, about fifteen months, from a survey with a low response rate.</li><li>Gray's jobs result relies on state unemployment-insurance records, which can miss self-employment and informal work.</li><li>Neither study examined hardship, health, or food security, and neither saw individual reasons for leaving.</li><li>"No clear change" means the margins were wide; it isn't the same as "no change."</li><li>The versions discussed are the peer-reviewed journal articles. The SNAP study first circulated as a working paper.</li><li>Rules are changing quickly. The federal rules described in the episode were current as of Nov. 13, 2026.</li></ul><p><strong>Credits</strong></p><p>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music created with Eleven Music. Website: frompeertoear.com. Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Starting January 1, 2027, many adults on expansion Medicaid will have to document work, volunteering, or school to keep their coverage, and the federal rules for SNAP work requirements are being rewritten too. So what did researchers find when work requirements were actually tried? In Episode 2, Emma and Ezra look at two peer-reviewed studies.</p><p><br></p><p>The first followed Virginia SNAP participants when the state brought its work rule back in 2013, using a birthday cutoff at age fifty as a natural experiment: many more people left the program, and the study could not detect a gain in employment. The second looked at Georgia, the first state to attach work requirements to a Medicaid expansion: no clear change in coverage or employment against neighboring states, and coverage that lagged South Dakota, which expanded without a requirement. Along the way: why "no detectable gain" isn't "no gain," how turning fifty can work as an experiment, and three neutral questions to ask of any proposal.</p><p><br></p><p>This episode doesn't tell you what to think about these rules; it covers what the research found.</p><p><br></p><p><strong>What to take away</strong></p><ul><li>What the studies support: in Virginia, the SNAP work rule went with many more people leaving the program, and no detectable employment gain. In Georgia, Medicaid coverage did not clearly change against neighboring states, but lagged a state that expanded without a requirement.</li><li>What they can't tell us: what will happen to any one person, why people left, or how the new rules will play out. Neither study saw individual reasons for leaving.</li><li>A question for any proposal: compared to what? Is there a comparison group, and will anyone measure jobs and coverage, not just enrollment?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>If a rule changes, track who drops off and at which step. Neither study could see individual reasons, and that gap is visible from a front desk.</li><li>Three neutral questions for any proposal: Is there a comparison group? Will anyone measure jobs and coverage, not just enrollment? And for how long?</li><li>For the public: if rules change where you live, read your state agency's notices closely. The research doesn't yet say paperwork is the whole story.</li></ul><p><strong>The research</strong></p><ul><li>Gray, C., Leive, A., Prager, E., Pukelis, K., &amp; Zaki, M. (2023). Employed in a SNAP? The impact of work requirements on program participation and labor supply. American Economic Journal: Economic Policy, 15(1), 306–341. <a href="https://doi.org/10.1257/pol.20200561">https://doi.org/10.1257/pol.20200561</a> (The full article is behind the publisher's paywall. An earlier working paper is free from NBER: <a href="https://nber.org/papers/w28877">nber.org/papers/w28877</a>.)</li><li>Johnson, D. Y., Mein, S. A., Marinacci, L. X., Liu, M., &amp; Wadhera, R. K. (2025). Insurance coverage and employment after Medicaid expansion with work requirements: Quasi-experimental difference-in-differences study. BMJ, 390, e086792. <a href="https://doi.org/10.1136/bmj-2025-086792">https://doi.org/10.1136/bmj-2025-086792</a> (Open access.)</li></ul><p><strong>In the news</strong></p><ul><li>Courthouse News. <a href="https://courthousenews.com/judge-blocks-trump-administration-from-enforcing-new-medically-frail-medicaid-rule/">Judge blocks Trump administration from enforcing new "medically frail" Medicaid rule</a>. Oct. 29, 2026.</li><li>States Newsroom. <a href="https://www.newsfromthestates.com/node/435353">Judge strikes down Trump 'medical frailty' rule in Medicaid work requirements</a>. Oct. 29, 2026.</li><li>MPR News. <a href="https://www.mprnews.org/story/2026/10/30/judge-blocks-trump-administrations-medicaid-rule-forcing-sick-recipients-to-prove-frailty">Judge blocks Trump administration's Medicaid rule forcing sick recipients to prove frailty</a>. Oct. 30, 2026.</li><li>CBS Austin / TNND. <a href="https://cbsaustin.com/news/nation-world/federal-judge-blocks-trump-medicaid-work-rule-limits-on-medically-frail-exemptions">Federal judge blocks Trump Medicaid work-rule limits on 'medically frail' exemptions</a>. Late Oct. 2026.</li><li>Federal Register (public inspection). <a href="https://public-inspection.federalregister.gov/2026-22944.pdf">Modification to Work Requirements for Able-Bodied Adults</a> (USDA proposed rule, FNA-2025-0368). Filed Nov. 9; scheduled Nov. 10, 2026.</li><li>Stateline. <a href="https://stateline.org/2026/04/10/snap-work-requirements-dont-boost-jobs-but-drop-participation-research-finds/">SNAP work requirements don't boost jobs, but drop participation, research finds</a>. Apr. 10, 2026.</li><li>Stateline. <a href="https://stateline.org/2026/07/31/judge-rejects-states-bid-to-block-medicaid-work-rules/">Judge rejects states' bid to block Medicaid work rules</a>. Jul. 31, 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>The SNAP study is Virginia in the mid-2010s and is strongest for people near age fifty. The Medicaid study is one state, about fifteen months, from a survey with a low response rate.</li><li>Gray's jobs result relies on state unemployment-insurance records, which can miss self-employment and informal work.</li><li>Neither study examined hardship, health, or food security, and neither saw individual reasons for leaving.</li><li>"No clear change" means the margins were wide; it isn't the same as "no change."</li><li>The versions discussed are the peer-reviewed journal articles. The SNAP study first circulated as a working paper.</li><li>Rules are changing quickly. The federal rules described in the episode were current as of Nov. 13, 2026.</li></ul><p><strong>Credits</strong></p><p>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music created with Eleven Music. Website: frompeertoear.com. Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p>]]>
      </content:encoded>
      <pubDate>Fri, 13 Nov 2026 10:52:33 -0800</pubDate>
      <author>From Peer to Ear</author>
      <enclosure url="https://media.transistor.fm/db3a25bc/b51a23fa.mp3" length="13768699" type="audio/mpeg"/>
      <itunes:author>From Peer to Ear</itunes:author>
      <itunes:duration>573</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>Starting January 1, 2027, many adults on expansion Medicaid will have to document work, volunteering, or school to keep their coverage, and the federal rules for SNAP work requirements are being rewritten too. So what did researchers find when work requirements were actually tried? In Episode 2, Emma and Ezra look at two peer-reviewed studies.</p><p><br></p><p>The first followed Virginia SNAP participants when the state brought its work rule back in 2013, using a birthday cutoff at age fifty as a natural experiment: many more people left the program, and the study could not detect a gain in employment. The second looked at Georgia, the first state to attach work requirements to a Medicaid expansion: no clear change in coverage or employment against neighboring states, and coverage that lagged South Dakota, which expanded without a requirement. Along the way: why "no detectable gain" isn't "no gain," how turning fifty can work as an experiment, and three neutral questions to ask of any proposal.</p><p><br></p><p>This episode doesn't tell you what to think about these rules; it covers what the research found.</p><p><br></p><p><strong>What to take away</strong></p><ul><li>What the studies support: in Virginia, the SNAP work rule went with many more people leaving the program, and no detectable employment gain. In Georgia, Medicaid coverage did not clearly change against neighboring states, but lagged a state that expanded without a requirement.</li><li>What they can't tell us: what will happen to any one person, why people left, or how the new rules will play out. Neither study saw individual reasons for leaving.</li><li>A question for any proposal: compared to what? Is there a comparison group, and will anyone measure jobs and coverage, not just enrollment?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>If a rule changes, track who drops off and at which step. Neither study could see individual reasons, and that gap is visible from a front desk.</li><li>Three neutral questions for any proposal: Is there a comparison group? Will anyone measure jobs and coverage, not just enrollment? And for how long?</li><li>For the public: if rules change where you live, read your state agency's notices closely. The research doesn't yet say paperwork is the whole story.</li></ul><p><strong>The research</strong></p><ul><li>Gray, C., Leive, A., Prager, E., Pukelis, K., &amp; Zaki, M. (2023). Employed in a SNAP? The impact of work requirements on program participation and labor supply. American Economic Journal: Economic Policy, 15(1), 306–341. <a href="https://doi.org/10.1257/pol.20200561">https://doi.org/10.1257/pol.20200561</a> (The full article is behind the publisher's paywall. An earlier working paper is free from NBER: <a href="https://nber.org/papers/w28877">nber.org/papers/w28877</a>.)</li><li>Johnson, D. Y., Mein, S. A., Marinacci, L. X., Liu, M., &amp; Wadhera, R. K. (2025). Insurance coverage and employment after Medicaid expansion with work requirements: Quasi-experimental difference-in-differences study. BMJ, 390, e086792. <a href="https://doi.org/10.1136/bmj-2025-086792">https://doi.org/10.1136/bmj-2025-086792</a> (Open access.)</li></ul><p><strong>In the news</strong></p><ul><li>Courthouse News. <a href="https://courthousenews.com/judge-blocks-trump-administration-from-enforcing-new-medically-frail-medicaid-rule/">Judge blocks Trump administration from enforcing new "medically frail" Medicaid rule</a>. Oct. 29, 2026.</li><li>States Newsroom. <a href="https://www.newsfromthestates.com/node/435353">Judge strikes down Trump 'medical frailty' rule in Medicaid work requirements</a>. Oct. 29, 2026.</li><li>MPR News. <a href="https://www.mprnews.org/story/2026/10/30/judge-blocks-trump-administrations-medicaid-rule-forcing-sick-recipients-to-prove-frailty">Judge blocks Trump administration's Medicaid rule forcing sick recipients to prove frailty</a>. Oct. 30, 2026.</li><li>CBS Austin / TNND. <a href="https://cbsaustin.com/news/nation-world/federal-judge-blocks-trump-medicaid-work-rule-limits-on-medically-frail-exemptions">Federal judge blocks Trump Medicaid work-rule limits on 'medically frail' exemptions</a>. Late Oct. 2026.</li><li>Federal Register (public inspection). <a href="https://public-inspection.federalregister.gov/2026-22944.pdf">Modification to Work Requirements for Able-Bodied Adults</a> (USDA proposed rule, FNA-2025-0368). Filed Nov. 9; scheduled Nov. 10, 2026.</li><li>Stateline. <a href="https://stateline.org/2026/04/10/snap-work-requirements-dont-boost-jobs-but-drop-participation-research-finds/">SNAP work requirements don't boost jobs, but drop participation, research finds</a>. Apr. 10, 2026.</li><li>Stateline. <a href="https://stateline.org/2026/07/31/judge-rejects-states-bid-to-block-medicaid-work-rules/">Judge rejects states' bid to block Medicaid work rules</a>. Jul. 31, 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>The SNAP study is Virginia in the mid-2010s and is strongest for people near age fifty. The Medicaid study is one state, about fifteen months, from a survey with a low response rate.</li><li>Gray's jobs result relies on state unemployment-insurance records, which can miss self-employment and informal work.</li><li>Neither study examined hardship, health, or food security, and neither saw individual reasons for leaving.</li><li>"No clear change" means the margins were wide; it isn't the same as "no change."</li><li>The versions discussed are the peer-reviewed journal articles. The SNAP study first circulated as a working paper.</li><li>Rules are changing quickly. The federal rules described in the episode were current as of Nov. 13, 2026.</li></ul><p><strong>Credits</strong></p><p>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music created with Eleven Music. Website: frompeertoear.com. Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p>]]>
      </itunes:summary>
      <itunes:keywords>research, peer-reviewed, policy, social science, economics, public policy, SNAP, Medicaid, work requirements, evidence-based, science communication</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Fentanyl Penalties and Overdose Deaths</title>
      <itunes:episode>1</itunes:episode>
      <podcast:episode>1</podcast:episode>
      <itunes:title>Fentanyl Penalties and Overdose Deaths</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">08a3145e-8bc9-424b-9b44-8971822f00cc</guid>
      <link>https://share.transistor.fm/s/9055817f</link>
      <description>
        <![CDATA[<p>Overdose deaths in the U.S. have fallen three years in a row, and everybody has a theory about why. In our first episode, Emma and Ezra look at what peer-reviewed research can and can't tell us about one of those theories: criminal penalties for drug possession.</p><p><br></p><p>Colorado made possessing small amounts of fentanyl a felony in 2022. Oregon went the other direction in 2021 and decriminalized possessing small amounts of every drug. Two studies, two directions, one narrower question: when a state changes the penalty for possession, do overdose deaths change? Neither study found a detectable change, and both are honest about what they can't show. Along the way: why "no detectable change" isn't the same as "no effect," how researchers build a statistical twin of a state, and three questions worth asking of any proposal.</p><p><br></p><p>Colorado voters approved Proposition 132 on November 3, 2026. This episode doesn't tell you how to vote or what policy to adopt; it covers what the research found.</p><p><br></p><p><strong>What to take away</strong></p><ul><li>What the studies support: in Colorado and Oregon, changing the penalty for possession didn't detectably change overall overdose deaths (in Oregon, once the drug supply is accounted for).</li><li>What they can't tell us: why deaths are falling nationally. Both studies cover years before the national decline, and neither is an experiment.</li><li>A question for any proposal: compared to what? Is there a comparison group, and does the analysis account for the drug supply?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>A law rarely arrives alone. Colorado's law also expanded harm reduction and jail treatment in 2023, so no single piece gets all the credit or all the blame.</li><li>Three questions worth asking of any proposal: Is there a comparison group? Does the analysis account for the drug supply? Will anyone track what happens, such as how often the law is actually charged?</li><li>These studies speak to possession penalties only. They don't test Proposition 132 itself, which goes further than Colorado's 2022 law.</li></ul><p><strong>The research</strong></p><ul><li>Jurecka, C., Adams, J., Padmanabhan, P., Glanz, J., Christine, P., Guan, X., Kline, D., Binswanger, I., &amp; Barocas, J. (2025). Implementation of a statewide fentanyl possession law and opioid-related overdose deaths. JAMA Health Forum, 6(8), e252654. <a href="https://doi.org/10.1001/jamahealthforum.2025.2654">https://doi.org/10.1001/jamahealthforum.2025.2654</a></li><li>Zoorob, M. J., Park, J. N., Kral, A. H., Lambdin, B. H., &amp; del Pozo, B. (2024). Drug decriminalization, fentanyl, and fatal overdoses in Oregon. JAMA Network Open, 7(9), e2431612. <a href="https://doi.org/10.1001/jamanetworkopen.2024.31612">https://doi.org/10.1001/jamanetworkopen.2024.31612</a></li></ul><p><strong>In the news</strong></p><ul><li>CDC National Center for Health Statistics. <a href="https://www.cdc.gov/nchs/pressroom/releases/20260513.html">U.S. Overdose Deaths Decrease for Third Consecutive Year in 2025</a>. May 13, 2026.</li><li>Fox News. <a href="https://www.foxnews.com/politics/exclusive-fentanyl-deaths-plunge-22-trump-white-house-touts-crackdown-deadly-drug-crisis">Fentanyl deaths plunge 22% as Trump White House touts crackdown on deadly drug crisis</a>. Aug. 21, 2026. (The White House's claim.)</li><li>WUSF / Florida Phoenix. <a href="https://www.wusf.org/health-news-florida/2026-10-23/desantis-tough-fentanyl-laws-have-led-to-60-dip-in-drug-deaths-in-three-years">DeSantis: Tough fentanyl laws have led to 60% dip in drug deaths in three years</a>. Oct. 23, 2026. (The governor's claim.)</li><li>STAT (First Opinion). <a href="https://www.statnews.com/2026/10/23/opioid-deaths-fallen-naloxone-treatment-supply-shock-public-health/">Overdose deaths have plunged. We need to know why</a>. Oct. 23, 2026. (Opinion.)</li><li>CBS News Colorado. Coverage of the Proposition 132 result. Nov. 6, 2026.</li><li>Colorado Legislative Council. Blue Book: Increase penalties for fentanyl crimes (Proposition 132). 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>Neither study is an experiment, so neither proves cause and effect.</li><li>Colorado had no comparison state and no data on how often the new felony was charged.</li><li>Oregon's estimate is imprecise, and its fentanyl measure (from police lab samples) only approximates the street.</li><li>Neither study tests Proposition 132 itself.</li></ul><p><strong>Credits</strong></p><p>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music created with Eleven Music. Website: frompeertoear.com. Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Overdose deaths in the U.S. have fallen three years in a row, and everybody has a theory about why. In our first episode, Emma and Ezra look at what peer-reviewed research can and can't tell us about one of those theories: criminal penalties for drug possession.</p><p><br></p><p>Colorado made possessing small amounts of fentanyl a felony in 2022. Oregon went the other direction in 2021 and decriminalized possessing small amounts of every drug. Two studies, two directions, one narrower question: when a state changes the penalty for possession, do overdose deaths change? Neither study found a detectable change, and both are honest about what they can't show. Along the way: why "no detectable change" isn't the same as "no effect," how researchers build a statistical twin of a state, and three questions worth asking of any proposal.</p><p><br></p><p>Colorado voters approved Proposition 132 on November 3, 2026. This episode doesn't tell you how to vote or what policy to adopt; it covers what the research found.</p><p><br></p><p><strong>What to take away</strong></p><ul><li>What the studies support: in Colorado and Oregon, changing the penalty for possession didn't detectably change overall overdose deaths (in Oregon, once the drug supply is accounted for).</li><li>What they can't tell us: why deaths are falling nationally. Both studies cover years before the national decline, and neither is an experiment.</li><li>A question for any proposal: compared to what? Is there a comparison group, and does the analysis account for the drug supply?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>A law rarely arrives alone. Colorado's law also expanded harm reduction and jail treatment in 2023, so no single piece gets all the credit or all the blame.</li><li>Three questions worth asking of any proposal: Is there a comparison group? Does the analysis account for the drug supply? Will anyone track what happens, such as how often the law is actually charged?</li><li>These studies speak to possession penalties only. They don't test Proposition 132 itself, which goes further than Colorado's 2022 law.</li></ul><p><strong>The research</strong></p><ul><li>Jurecka, C., Adams, J., Padmanabhan, P., Glanz, J., Christine, P., Guan, X., Kline, D., Binswanger, I., &amp; Barocas, J. (2025). Implementation of a statewide fentanyl possession law and opioid-related overdose deaths. JAMA Health Forum, 6(8), e252654. <a href="https://doi.org/10.1001/jamahealthforum.2025.2654">https://doi.org/10.1001/jamahealthforum.2025.2654</a></li><li>Zoorob, M. J., Park, J. N., Kral, A. H., Lambdin, B. H., &amp; del Pozo, B. (2024). Drug decriminalization, fentanyl, and fatal overdoses in Oregon. JAMA Network Open, 7(9), e2431612. <a href="https://doi.org/10.1001/jamanetworkopen.2024.31612">https://doi.org/10.1001/jamanetworkopen.2024.31612</a></li></ul><p><strong>In the news</strong></p><ul><li>CDC National Center for Health Statistics. <a href="https://www.cdc.gov/nchs/pressroom/releases/20260513.html">U.S. Overdose Deaths Decrease for Third Consecutive Year in 2025</a>. May 13, 2026.</li><li>Fox News. <a href="https://www.foxnews.com/politics/exclusive-fentanyl-deaths-plunge-22-trump-white-house-touts-crackdown-deadly-drug-crisis">Fentanyl deaths plunge 22% as Trump White House touts crackdown on deadly drug crisis</a>. Aug. 21, 2026. (The White House's claim.)</li><li>WUSF / Florida Phoenix. <a href="https://www.wusf.org/health-news-florida/2026-10-23/desantis-tough-fentanyl-laws-have-led-to-60-dip-in-drug-deaths-in-three-years">DeSantis: Tough fentanyl laws have led to 60% dip in drug deaths in three years</a>. Oct. 23, 2026. (The governor's claim.)</li><li>STAT (First Opinion). <a href="https://www.statnews.com/2026/10/23/opioid-deaths-fallen-naloxone-treatment-supply-shock-public-health/">Overdose deaths have plunged. We need to know why</a>. Oct. 23, 2026. (Opinion.)</li><li>CBS News Colorado. Coverage of the Proposition 132 result. Nov. 6, 2026.</li><li>Colorado Legislative Council. Blue Book: Increase penalties for fentanyl crimes (Proposition 132). 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>Neither study is an experiment, so neither proves cause and effect.</li><li>Colorado had no comparison state and no data on how often the new felony was charged.</li><li>Oregon's estimate is imprecise, and its fentanyl measure (from police lab samples) only approximates the street.</li><li>Neither study tests Proposition 132 itself.</li></ul><p><strong>Credits</strong></p><p>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music created with Eleven Music. Website: frompeertoear.com. Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p>]]>
      </content:encoded>
      <pubDate>Thu, 12 Nov 2026 13:37:51 -0800</pubDate>
      <author>From Peer to Ear</author>
      <enclosure url="https://media.transistor.fm/9055817f/1b32830c.mp3" length="14146632" type="audio/mpeg"/>
      <itunes:author>From Peer to Ear</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/XJqB7DjE1gLDfqsd5zYq4nYiZXocZy4dNmpLhQjCneQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wYmE1/OWI5ZjI2OTlmYWVl/NWZkZWE3MjU5ODg0/NzkwMy5wbmc.jpg"/>
      <itunes:duration>589</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>Overdose deaths in the U.S. have fallen three years in a row, and everybody has a theory about why. In our first episode, Emma and Ezra look at what peer-reviewed research can and can't tell us about one of those theories: criminal penalties for drug possession.</p><p><br></p><p>Colorado made possessing small amounts of fentanyl a felony in 2022. Oregon went the other direction in 2021 and decriminalized possessing small amounts of every drug. Two studies, two directions, one narrower question: when a state changes the penalty for possession, do overdose deaths change? Neither study found a detectable change, and both are honest about what they can't show. Along the way: why "no detectable change" isn't the same as "no effect," how researchers build a statistical twin of a state, and three questions worth asking of any proposal.</p><p><br></p><p>Colorado voters approved Proposition 132 on November 3, 2026. This episode doesn't tell you how to vote or what policy to adopt; it covers what the research found.</p><p><br></p><p><strong>What to take away</strong></p><ul><li>What the studies support: in Colorado and Oregon, changing the penalty for possession didn't detectably change overall overdose deaths (in Oregon, once the drug supply is accounted for).</li><li>What they can't tell us: why deaths are falling nationally. Both studies cover years before the national decline, and neither is an experiment.</li><li>A question for any proposal: compared to what? Is there a comparison group, and does the analysis account for the drug supply?</li></ul><p><strong>For practitioners and policymakers</strong></p><ul><li>A law rarely arrives alone. Colorado's law also expanded harm reduction and jail treatment in 2023, so no single piece gets all the credit or all the blame.</li><li>Three questions worth asking of any proposal: Is there a comparison group? Does the analysis account for the drug supply? Will anyone track what happens, such as how often the law is actually charged?</li><li>These studies speak to possession penalties only. They don't test Proposition 132 itself, which goes further than Colorado's 2022 law.</li></ul><p><strong>The research</strong></p><ul><li>Jurecka, C., Adams, J., Padmanabhan, P., Glanz, J., Christine, P., Guan, X., Kline, D., Binswanger, I., &amp; Barocas, J. (2025). Implementation of a statewide fentanyl possession law and opioid-related overdose deaths. JAMA Health Forum, 6(8), e252654. <a href="https://doi.org/10.1001/jamahealthforum.2025.2654">https://doi.org/10.1001/jamahealthforum.2025.2654</a></li><li>Zoorob, M. J., Park, J. N., Kral, A. H., Lambdin, B. H., &amp; del Pozo, B. (2024). Drug decriminalization, fentanyl, and fatal overdoses in Oregon. JAMA Network Open, 7(9), e2431612. <a href="https://doi.org/10.1001/jamanetworkopen.2024.31612">https://doi.org/10.1001/jamanetworkopen.2024.31612</a></li></ul><p><strong>In the news</strong></p><ul><li>CDC National Center for Health Statistics. <a href="https://www.cdc.gov/nchs/pressroom/releases/20260513.html">U.S. Overdose Deaths Decrease for Third Consecutive Year in 2025</a>. May 13, 2026.</li><li>Fox News. <a href="https://www.foxnews.com/politics/exclusive-fentanyl-deaths-plunge-22-trump-white-house-touts-crackdown-deadly-drug-crisis">Fentanyl deaths plunge 22% as Trump White House touts crackdown on deadly drug crisis</a>. Aug. 21, 2026. (The White House's claim.)</li><li>WUSF / Florida Phoenix. <a href="https://www.wusf.org/health-news-florida/2026-10-23/desantis-tough-fentanyl-laws-have-led-to-60-dip-in-drug-deaths-in-three-years">DeSantis: Tough fentanyl laws have led to 60% dip in drug deaths in three years</a>. Oct. 23, 2026. (The governor's claim.)</li><li>STAT (First Opinion). <a href="https://www.statnews.com/2026/10/23/opioid-deaths-fallen-naloxone-treatment-supply-shock-public-health/">Overdose deaths have plunged. We need to know why</a>. Oct. 23, 2026. (Opinion.)</li><li>CBS News Colorado. Coverage of the Proposition 132 result. Nov. 6, 2026.</li><li>Colorado Legislative Council. Blue Book: Increase penalties for fentanyl crimes (Proposition 132). 2026.</li></ul><p><strong>The fine print</strong></p><ul><li>Neither study is an experiment, so neither proves cause and effect.</li><li>Colorado had no comparison state and no data on how often the new felony was charged.</li><li>Oregon's estimate is imprecise, and its fentanyl measure (from police lab samples) only approximates the street.</li><li>Neither study tests Proposition 132 itself.</li></ul><p><strong>Credits</strong></p><p>Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs). Outro music created with Eleven Music. Website: frompeertoear.com. Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we'll fix it.</p><p><br></p><p>This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.</p>]]>
      </itunes:summary>
      <itunes:keywords>research, peer-reviewed, policy, criminology, evidence-based, science communication</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
  </channel>
</rss>
